Michael Prof. Dr. Weller
#75,786
Most Influential Person Now
Michael Prof. Dr. Weller's AcademicInfluence.com Rankings
Michael Prof. Dr. Wellerphilosophy Degrees
Philosophy
#2555
World Rank
#4336
Historical Rank
Logic
#643
World Rank
#1132
Historical Rank
Download Badge
Physics Philosophy
Michael Prof. Dr. Weller's Degrees
- PhD Neurology University of Zurich
Why Is Michael Prof. Dr. Weller Influential?
(Suggest an Edit or Addition)Michael Prof. Dr. Weller's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. (2005) (16695)
- Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. (2009) (6397)
- MGMT gene silencing and benefit from temozolomide in glioblastoma. (2005) (4989)
- DNA methylation-based classification of central nervous system tumours (2018) (1461)
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor (2011) (1423)
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial (2017) (1217)
- Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas (2009) (1062)
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. (2012) (925)
- Long-term survival with glioblastoma multiforme. (2007) (812)
- NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. (2009) (779)
- Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity. (2008) (747)
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. (2014) (744)
- Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo (2002) (742)
- European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. (2017) (736)
- Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas (2010) (714)
- Current state of immunotherapy for glioblastoma (2018) (684)
- MGMT promoter methylation in malignant gliomas: ready for personalized medicine? (2010) (667)
- EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. (2014) (601)
- Standards of care for treatment of recurrent glioblastoma--are we there yet? (2013) (582)
- Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. (2009) (561)
- Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. (2016) (550)
- Lomustine and Bevacizumab in Progressive Glioblastoma (2017) (540)
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma (2020) (537)
- Ceramide accumulation mediates inflammation, cell death and infection susceptibility in cystic fibrosis (2008) (529)
- EANO guidelines for the diagnosis and treatment of meningiomas. (2016) (524)
- Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3. (2008) (496)
- cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” (2018) (492)
- EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood (2020) (486)
- Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. (2015) (486)
- Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. (2001) (481)
- High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. (2010) (476)
- Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. (2010) (460)
- Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. (2017) (452)
- Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine (2007) (452)
- DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. (2017) (447)
- Advances in the molecular genetics of gliomas — implications for classification and therapy (2017) (446)
- Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. (2015) (438)
- Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. (2015) (436)
- Current concepts and management of glioblastoma (2011) (429)
- SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma Cells In vitro and In vivo (2004) (416)
- MGMT testing—the challenges for biomarker-based glioma treatment (2014) (413)
- Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. (2003) (396)
- Changing paradigms--an update on the multidisciplinary management of malignant glioma. (2006) (394)
- Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. Induction and modulation of sensitivity by cytokines. (1994) (376)
- Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions. (2020) (367)
- ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma (2014) (367)
- The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis (1995) (360)
- Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients (2005) (343)
- A Functional Role of HLA-G Expression in Human Gliomas: An Alternative Strategy of Immune Escape1 (2002) (341)
- Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. (2010) (338)
- Potassium Deprivation-Induced Apoptosis of Cerebellar Granule Neurons: A Sequential Requirement for New mRNA and Protein Synthesis, ICE-Like Protease Activity, and Reactive Oxygen Species (1996) (332)
- Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma (2008) (325)
- Caspases as treatment targets in stroke and neurodegenerative diseases (1999) (321)
- Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology (EANO) (2017) (312)
- Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties. (1994) (307)
- Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. (2015) (303)
- RNA Interference Targeting Transforming Growth Factor-β Enhances NKG2D-Mediated Antiglioma Immune Response, Inhibits Glioma Cell Migration and Invasiveness, and Abrogates Tumorigenicity In vivo (2004) (303)
- ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis (2013) (298)
- Molecular targeted therapy of glioblastoma. (2019) (295)
- cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading (2020) (293)
- Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma (2017) (291)
- Toll‐Like Receptor Engagement Enhances the Immunosuppressive Properties of Human Bone Marrow‐Derived Mesenchymal Stem Cells by Inducing Indoleamine‐2,3‐dioxygenase‐1 via Interferon‐β and Protein Kinase R (2009) (290)
- O6‐methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells (2006) (290)
- Neuroprotection by Hypoxic Preconditioning Requires Sequential Activation of Vascular Endothelial Growth Factor Receptor and Akt (2002) (287)
- Interferon-β enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis (2004) (278)
- Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial (2019) (275)
- Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide trial for glioblastoma (2011) (273)
- Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0 (2018) (271)
- Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. (1995) (271)
- Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study (2017) (271)
- Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes (2020) (270)
- The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-β, T-cell apoptosis, and the immune privilege of the brain (1995) (267)
- MRI features of primary central nervous system lymphomas at presentation (2001) (265)
- Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas (2011) (264)
- Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate (2018) (264)
- Glioma Cell Invasion: Regulation of Metalloproteinase Activity by TGF-β (2001) (260)
- MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial (2015) (256)
- Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system (2013) (254)
- cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas (2020) (253)
- Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma. (2007) (252)
- Immunosuppressive mechanisms in glioblastoma. (2015) (249)
- Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups (2015) (245)
- MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status (2012) (242)
- Corticosteroids compromise survival in glioblastoma. (2016) (239)
- Monocyte chemoattractant protein–1 increases microglial infiltration and aggressiveness of gliomas (2003) (237)
- Novel, improved grading system(s) for IDH-mutant astrocytic gliomas (2018) (236)
- Predicting response to cancer chemotherapy: the role of p53 (1998) (235)
- Predictive impact of MGMT promoter methylation in glioblastoma of the elderly (2012) (234)
- Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. (2001) (232)
- Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities (2015) (230)
- Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in athymic mice in the absence of neurotoxicity. (1999) (229)
- Psychotogenicity and N-methyl-D-aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy (1997) (226)
- Signaling from cAMP/PKA to MAPK and synaptic plasticity (2003) (224)
- LONGITUDINAL MOLECULAR TRAJECTORIES OF DIFFUSE GLIOMA IN ADULTS (2019) (223)
- EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. (2013) (223)
- ERGO: A pilot study of ketogenic diet in recurrent glioblastoma (2014) (222)
- APO2 ligand: a novel lethal weapon against malignant glioma? (1998) (212)
- Local Fas/APO‐1 (CD95) ligand‐mediated tumor cell killing in vivo (1995) (208)
- Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation (2013) (204)
- Protection by Synergistic Effects of Adenovirus-Mediated X-Chromosome-Linked Inhibitor of Apoptosis and Glial Cell Line-Derived Neurotrophic Factor Gene Transfer in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease (2000) (202)
- Glioma (2015) (202)
- MICA/NKG2D-mediated immunogene therapy of experimental gliomas. (2003) (201)
- Induction of Nitric Oxide Synthase and Nitric Oxide‐Mediated Apoptosis in Neuronal PC12 Cells After Stimulation with Tumor Necrosis FActor‐α/Lipopolysaccharide (1998) (193)
- Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice. (2012) (189)
- Surgery for primary CNS lymphoma? Challenging a paradigm. (2012) (185)
- Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. (2015) (183)
- Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma. (2002) (182)
- Molecular neuro-oncology in clinical practice: a new horizon. (2013) (182)
- TGF-β and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells (2006) (181)
- Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma (2014) (180)
- Depolarization or glutamate receptor activation blocks apoptotic cell death of cultured cerebellar granule neurons (1994) (180)
- NOA‐03 trial of high‐dose methotrexate in primary central nervous system lymphoma: Final report (2005) (179)
- Predicting chemoresistance in human malignant glioma cells: The role of molecular genetic analyses (1998) (177)
- Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy. (2013) (173)
- Glioblastoma stem cells (2011) (173)
- Genetic signature of oligoastrocytomas correlates with tumor location and denotes distinct molecular subsets. (2002) (172)
- EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. (2017) (171)
- Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic? (2011) (171)
- Secreted Frizzled-related proteins inhibit motility and promote growth of human malignant glioma cells (2000) (171)
- Ocular myasthenia gravis: response to long-term immunosuppressive treatment. (1997) (169)
- Invasion patterns in brain metastases of solid cancers. (2013) (168)
- CAMTA1 is a novel tumour suppressor regulated by miR‐9/9* in glioblastoma stem cells (2011) (167)
- Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. (2015) (166)
- Intratumoral IL-12 combined with CTLA-4 blockade elicits T cell–mediated glioma rejection (2013) (164)
- A specific miRNA signature in the peripheral blood of glioblastoma patients (2011) (164)
- One week on/one week off: A novel active regimen of temozolomide for recurrent glioblastoma (2004) (162)
- Eradication of glioblastoma, and breast and colon carcinoma xenografts by Hsp70 depletion. (2002) (160)
- European Association for Neuro-Oncology (EANO) guidelines for palliative care in adults with glioma. (2017) (160)
- German Cancer Society Neuro‐Oncology Working Group NOA‐03 multicenter trial of single‐agent high‐dose methotrexate for primary central nervous system lymphoma (2002) (159)
- Therapeutic options in recurrent glioblastoma--An update. (2016) (159)
- New (alternative) temozolomide regimens for the treatment of glioma. (2009) (157)
- Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity. (2005) (155)
- Pathway inhibition: emerging molecular targets for treating glioblastoma. (2011) (155)
- NKG2D-Based CAR T Cells and Radiotherapy Exert Synergistic Efficacy in Glioblastoma. (2018) (155)
- Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations (2018) (154)
- Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma (2018) (154)
- Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors (2006) (153)
- Molecular diagnostics of gliomas: the clinical perspective (2010) (153)
- HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. (2005) (153)
- Boswellic acids and malignant glioma: induction of apoptosis but no modulation of drug sensitivity (1999) (152)
- Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase Mutations (2013) (152)
- CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death (2003) (151)
- Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03. (2006) (151)
- Betulinic acid-induced apoptosis in glioma cells: A sequential requirement for new protein synthesis, formation of reactive oxygen species, and caspase processing. (1999) (147)
- Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide (2010) (145)
- Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression. (2000) (144)
- mTOR target NDRG1 confers MGMT-dependent resistance to alkylating chemotherapy (2013) (141)
- Transforming growth factor-beta: a molecular target for the future therapy of glioblastoma. (2006) (138)
- Evolutionary Trajectories of IDHWT Glioblastomas Reveal a Common Path of Early Tumorigenesis Instigated Years ahead of Initial Diagnosis. (2019) (138)
- Transforming growth factor-β and p-21: multiple molecular targets of decorin-mediated suppression of neoplastic growth (1999) (138)
- PTEN methylation and expression in glioblastomas (2003) (137)
- TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells. (2006) (137)
- Leptomeningeal metastasis: survival and prognostic factors in 155 patients (2004) (135)
- PET imaging in patients with meningioma—report of the RANO/PET Group (2017) (135)
- Molecular determinants of glioma cell migration and invasion. (2001) (135)
- EANO guidelines for the diagnosis and treatment of ependymal tumors. (2018) (134)
- Chapter 23 - Glioblastoma (2016) (134)
- Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma. (2003) (132)
- BCL-2 Family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy (1999) (132)
- Fas/APO-1 gene transfer for human malignant glioma. (1995) (132)
- Optimal management of elderly patients with glioblastoma. (2013) (132)
- Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. (2016) (131)
- Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM (2015) (131)
- Combined 1p/19q Loss in Oligodendroglial Tumors: Predictive or Prognostic Biomarker? (2007) (130)
- Fas/CD95/Apo-I activates the acidic sphingomyelinase via Caspases (1998) (127)
- Expression pattern of the water channel aquaporin‐4 in human gliomas is associated with blood–brain barrier disturbance but not with patient survival (2007) (127)
- GDF-15 Contributes to Proliferation and Immune Escape of Malignant Gliomas (2010) (127)
- PTEN gene transfer in human malignant glioma: sensitization to irradiation and CD95L-induced apoptosis (1999) (126)
- Transforming growth factor‐β2 induces apoptosis of murine T cell clones without down‐regulating bcl‐2 mRNA expression (1994) (125)
- Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide. (2009) (125)
- Epilepsy meets cancer: when, why, and what to do about it? (2012) (124)
- Antiepileptic drugs interact with folate and vitamin B12 serum levels (2011) (124)
- Prognostic Value of Three Different Methods of MGMT Promoter Methylation Analysis in a Prospective Trial on Newly Diagnosed Glioblastoma (2012) (123)
- Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells (2012) (121)
- Apoptosis in human alveolar macrophages is induced by endotoxin and is modulated by cytokines. (1996) (120)
- Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies. (2003) (120)
- Cooperative Interception of Neuronal Apoptosis by BCL‐2 and BAG‐1 Expression: Prevention of Caspase Activation and Reduced Production of Reactive Oxygen Species (1997) (120)
- Molecular characterization of long‐term survivors of glioblastoma using genome‐ and transcriptome‐wide profiling (2014) (117)
- Anterior opercular cortex lesions cause dissociated lower cranial nerve palsies and anarthria but no aphasia: Foix-Chavany-Marie syndrome and “automatic voluntary dissociation” revisited (2004) (117)
- Decorin gene transfer-mediated suppression of TGF-β synthesis abrogates experimental malignant glioma growth in vivo (1998) (117)
- Expression and biological activity of X-linked inhibitor of apoptosis (XIAP) in human malignant glioma (1999) (117)
- Therapeutic anti‐tumor immunity triggered by injections of immunostimulating single‐stranded RNA (2006) (116)
- Suberoylanilide hydroxamic acid (SAHA) has potent anti‐glioma properties in vitro, ex vivo and in vivo (2005) (116)
- Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-β-dependent HIF-1α-mediated induction of CXCL12 (2006) (116)
- Glucocorticoid Treatment of Primary CNS Lymphoma (1999) (116)
- Vaccine-based immunotherapeutic approaches to gliomas and beyond (2017) (116)
- Human muscle cells express a B7‐related molecule, B7‐H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies (2003) (115)
- Bevacizumab and recurrent malignant gliomas: a European perspective. (2010) (115)
- EANO Guideline on the Diagnosis and Treatment of Vestibular Schwannoma. (2019) (115)
- A clinical perspective on the 2016 WHO brain tumor classification and routine molecular diagnostics (2017) (114)
- Epidermal Growth Factor Receptor Variant III (EGFRvIII) Positivity in EGFR-Amplified Glioblastomas: Prognostic Role and Comparison between Primary and Recurrent Tumors (2017) (114)
- Patterns of cyclooxygenase-1 and -2 expression in human gliomas in vivo (1999) (111)
- Macrophage Migration Inhibitory Factor Contributes to the Immune Escape of Ovarian Cancer by Down-Regulating NKG2D1 (2008) (110)
- Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. (2018) (110)
- Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (2016) (109)
- PET imaging in patients with brain metastasis-report of the RANO/PET group. (2019) (108)
- Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. (2002) (107)
- BCL‐2 promotes migration and invasiveness of human glioma cells (1998) (107)
- Neurological symptoms in patients with biopsy proven celiac disease (2009) (107)
- Human malignant glioma cells express semaphorins and their receptors, neuropilins and plexins (2003) (107)
- Processing of Immunosuppressive Pro-TGF-β1,2 by Human Glioblastoma Cells Involves Cytoplasmic and Secreted Furin-Like Proteases1 (2001) (105)
- Extended therapeutic window for caspase inhibition and synergy with MK-801 in the treatment of cerebral histotoxic hypoxia (1998) (105)
- Cell death and apoptosis regulating proteins in Parkinson’s disease – a cautionary note (1999) (104)
- Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG (2015) (104)
- Fatigue and excessive daytime sleepiness in idiopathic Parkinson’s disease differently correlate with motor symptoms, depression and dopaminergic treatment (2010) (104)
- Rechallenge with temozolomide in patients with recurrent gliomas (2009) (104)
- PIK3CA alterations in primary (de novo) and secondary glioblastomas (2007) (104)
- Integrin control of the transforming growth factor-β pathway in glioblastoma. (2013) (102)
- CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release (2001) (101)
- High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma. (2005) (101)
- PCV salvage chemotherapy for recurrent primary CNS lymphoma (2000) (101)
- Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness (2011) (101)
- Hypoxia-induced cell death in human malignant glioma cells: energy deprivation promotes decoupling of mitochondrial cytochrome c release from caspase processing and necrotic cell death (2003) (101)
- EANO guideline on the diagnosis and management of meningiomas. (2021) (101)
- Targeting integrins in malignant glioma (2010) (100)
- INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma (2019) (99)
- A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis (2008) (99)
- TP53 promoter methylation in human gliomas (2005) (99)
- Aryl hydrocarbon receptor inhibition downregulates the TGF-β/Smad pathway in human glioblastoma cells (2009) (98)
- Progressive dopamine and hypocretin deficiencies in Parkinson’s disease: is there an impact on sleep and wakefulness? (2012) (98)
- Ezrin-Dependent Promotion of Glioma Cell Clonogenicity, Motility, and Invasion Mediated by BCL-2 and Transforming Growth Factor-β2 (2001) (97)
- Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082) (2016) (97)
- MR Imaging of Neoplastic Central Nervous System Lesions: Review and Recommendations for Current Practice (2012) (96)
- Phosphoglycerate kinase 1 a promoting enzyme for peritoneal dissemination in gastric cancer (2010) (95)
- Assessment and prognostic significance of the epidermal growth factor receptor vIII mutation in glioblastoma patients treated with concurrent and adjuvant temozolomide radiochemotherapy (2014) (95)
- The non-classical MHC molecule HLA-G protects human muscle cells from immune-mediated lysis: implications for myoblast transplantation and gene therapy. (2003) (95)
- Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence (2018) (94)
- Consensus recommendations for a standardized brain tumor imaging protocol for clinical trials in brain metastases (BTIP-BM). (2020) (94)
- APRIL, a new member of the tumor necrosis factor family, modulates death ligand-induced apoptosis (2001) (93)
- Malignant glioma cells counteract antitumor immune responses through expression of lectin-like transcript-1. (2007) (92)
- Comparative analysis of cytokine patterns in immunological, infectious, and oncological neurological disorders (1991) (92)
- Cilengitide: an RGD pentapeptide ανβ3 and ανβ5 integrin inhibitor in development for glioblastoma and other malignancies. (2011) (92)
- Cerebellar ataxia with glutamic acid decarboxylase autoantibodies (1999) (91)
- LB-05PHASE III TRIAL EXPLORING THE COMBINATION OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST RECURRENCE OF A GLIOBLASTOMA: THE EORTC 26101 TRIAL (2015) (91)
- Meningeal dissemination in primary CNS lymphoma (2008) (90)
- S-Adenosylmethionine Is Decreased in the Cerebrospinal Fluid of Patients with Alzheimer’s Disease (2010) (90)
- Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro. (2009) (90)
- Inhibiting TGF-beta signaling restores immune surveillance in the SMA-560 glioma model. (2007) (90)
- Somatostatin receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to 68Ga-DOTATATE/-TOC uptake. (2016) (89)
- CANCER RISK AMONG PATIENTS WITH MULTIPLE SCLEROSIS AND THEIR PARENTS (2010) (88)
- CD95 Ligand: Lethal Weapon Against Malignant Glioma? (1998) (88)
- Lessons from the bone marrow: how malignant glioma cells attract adult haematopoietic progenitor cells. (2005) (87)
- Apoptotic cell death in the cerebellum of mutant weaver and lurcher mice (1995) (87)
- Cascade of Caspase Activation in Potassium-Deprived Cerebellar Granule Neurons: Targets for Treatment with Peptide and Protein Inhibitors of Apoptosis (2001) (87)
- A novel tool to analyze MRI recurrence patterns in glioblastoma. (2008) (87)
- Seizure control as a new metric in assessing efficacy of tumor treatment in low-grade glioma trials. (2017) (87)
- Randomized phase III study of whole-brain radiotherapy for primary CNS lymphoma (2015) (87)
- Steroids in neurooncology: actions, indications, side-effects. (2010) (86)
- Proposed response assessment and endpoints for meningioma clinical trials: report from the Response Assessment in Neuro-Oncology Working Group. (2018) (86)
- N‐[3,4‐dimethoxycinnamoyl]‐anthranilic acid (tranilast) inhibits transforming growth factor‐β release and reduces migration and invasiveness of human malignant glioma cells (2001) (85)
- Bevacizumab does not increase the risk of remote relapse in malignant glioma (2011) (85)
- EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours. (2017) (85)
- MicroRNA-mediated down-regulation of NKG2D ligands contributes to glioma immune escape (2014) (85)
- Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery (2017) (85)
- Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. (2013) (85)
- 2‐Hydroxyglutarate concentration in serum from patients with gliomas does not correlate with IDH1/2 mutation status or tumor size (2012) (85)
- Expression and functional activity of heat shock proteins in human glioblastoma multiforme (2000) (84)
- HSV-2 sacral radiculitis (Elsberg syndrome) (2004) (84)
- Topoisomerase‐I inhibitors for human malignant glioma: Differential modulation of p53, p21, bax and bcl‐2 expression and of CD95‐mediated apoptosis by camptothecin and β‐lapachone (1997) (83)
- Transforming growth factor-β pathway activity in glioblastoma (2015) (83)
- The topoisomerase II inhibitor, genistein, induces G2/M arrest and apoptosis in human malignant glioma cell lines. (2008) (82)
- αv‐Integrin isoform expression in primary human tumors and brain metastases (2013) (82)
- Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications (2019) (81)
- Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses. (2017) (80)
- Gliomatosis cerebri: Molecular pathology and clinical course (2002) (80)
- Synergistic antiglioma activity of radiotherapy and enzastaurin (2007) (80)
- Profiling walking dysfunction in multiple sclerosis: characterisation, classification and progression over time (2018) (80)
- PCV chemotherapy for recurrent glioblastoma (2006) (79)
- High level expression of expanded full-length ataxin-3 in vitro causes cell death and formation of intranuclear inclusions in neuronal cells. (1999) (79)
- Glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009 (2015) (78)
- Pharmacotherapy of Epileptic Seizures in Glioma Patients: Who, When, Why and How Long? (2005) (78)
- Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial (2012) (78)
- How did lomustine become standard of care in recurrent glioblastoma? (2020) (78)
- Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group (2004) (78)
- Induction of nitric oxide synthase and nitric oxide-mediated apoptosis in neuronal PC12 cells after stimulation with tumor necrosis factor-alpha/lipopolysaccharide. (1998) (77)
- Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma (2015) (77)
- Epidermal growth factor receptor: a re-emerging target in glioblastoma. (2012) (77)
- Individualized Targeted Therapy for Glioblastoma: Fact or Fiction? (2012) (77)
- BCL-2 family protein expression in human malignant glioma: a clinical-pathological correlative study (1998) (77)
- CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas (2020) (77)
- Surviving glioblastoma for more than 5 years: The patient's perspective (2006) (77)
- Consensus Recommendations for a Dynamic Susceptibility Contrast MRI Protocol for Use in High-Grade Gliomas. (2020) (76)
- Immune (dys)regulation in multiple sclerosis: role of the CD95-CD95 ligand system. (1999) (75)
- Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial. (2014) (75)
- Biological activity of tumor-treating fields in preclinical glioma models (2017) (75)
- MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials (2018) (74)
- Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-β in vitro and in vivo: rationale for the therapy of multiple sclerosis (2005) (74)
- Targeting apoptosis pathways in glioblastoma. (2013) (74)
- Inhibition of Epidermal Growth Factor Receptor Signaling Protects Human Malignant Glioma Cells from Hypoxia-Induced Cell Death (2004) (73)
- Pulmonary blastoma: a rare childhood malignancy. (1991) (73)
- Primary CNS lymphoma in the elderly: temozolomide therapy and MGMT status (2010) (73)
- Response of radiochemotherapy-associated cerebral edema to a phytotherapeutic agent, H15 (2001) (72)
- Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53. (1997) (72)
- Enhanced episodic‐like memory and kindling epilepsy in a rat model of tuberous sclerosis (2006) (72)
- Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model (2004) (72)
- Proliferative vitreoretinopathy — is it anything more than wound healing at the wrong place? (1990) (72)
- NMDA receptor-mediated glutamate toxicity of cultured cerebellar, cortical and mesencephalic neurons: neuroprotective properties of amantadine and memantine (1993) (72)
- Differential regulation of TGF-β-induced, ALK-5-mediated VEGF release by SMAD2/3 versus SMAD1/5/8 signaling in glioblastoma. (2014) (71)
- Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: Response, Progression, and Pseudoprogression. (2019) (71)
- Deletion of the ageing gene p66(Shc) reduces early stroke size following ischaemia/reperfusion brain injury. (2013) (71)
- The network of immunosuppressive pathways in glioblastoma (2017) (71)
- Proteasome inhibition leads to NF‐κB‐independent IL‐8 transactivation in human endothelial cells through induction of AP‐1 (2002) (71)
- Neutrophils Obstructing Brain Capillaries Are a Major Cause of No-Reflow in Ischemic Stroke. (2020) (70)
- Levetiracetam and pregabalin for antiepileptic monotherapy in patients with primary brain tumors. A phase II randomized study. (2014) (70)
- 68Gallium-DOTATATE PET in meningioma: A reliable predictor of tumor growth rate? (2016) (70)
- Dynamic 18F‐FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses (2015) (69)
- Macrophage migration inhibitory factor (MIF) expression in human malignant gliomas contributes to immune escape and tumour progression (2011) (69)
- Dexamethasone-mediated protection from drug cytotoxicity: association with p21WAF1/CIP1 protein accumulation? (1998) (69)
- HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy (2021) (69)
- Diffusion-weighted MRI of spinal cord infarction--high resolution imaging and time course of diffusion abnormality. (2004) (69)
- The pathophysiology of proliferative vitreoretinopathy. (1988) (69)
- Modulation of growth and radiochemosensitivity of human malignant glioma cells by acidosis (2002) (68)
- Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value (2004) (68)
- Management of low-grade glioma: a systematic review and meta-analysis. (2018) (68)
- Human autoreactive and foreign antigen-specific T cells resist apoptosis induced by soluble recombinant CD95 ligand. (1997) (68)
- Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. (2006) (67)
- Expression of TRAIL receptors in human autoreactive and foreign antigen-specific T cells (2000) (67)
- Gliomatosis cerebri: no evidence for a separate brain tumor entity (2016) (67)
- Chemotherapy of human malignant glioma (1997) (66)
- Apoptosis in proliferative vitreoretinal disorders: possible involvement of TGF-beta-induced RPE cell apoptosis. (1997) (66)
- Patterns of Progression in Malignant Glioma Following Anti-VEGF Therapy: Perceptions and Evidence (2011) (66)
- Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals. (2001) (66)
- Human astrocytic brain tumors express APO2L/TRAIL (1999) (66)
- Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells: association with bcl-2 phosphorylation but neither activation of p53 nor G2/M cell cycle arrest. (1998) (66)
- Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives (1999) (64)
- Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial. (2018) (64)
- Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma (2018) (64)
- Apoptosis in Gliomas: Molecular Mechanisms and Therapeutic Implications (2004) (64)
- Crm-A, bcl-2 and NDGA inhibit CD95L-induced apoptosis of malignant glioma cells at the level of caspase 8 processing (1998) (64)
- Proteasome Inhibitors Induce p53/p21-Independent Apoptosis in Human Glioma Cells (1999) (64)
- EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine in patients with first progression of a glioblastoma. (2016) (63)
- Elevated HLA-E levels in human glioblastomas but not in grade I to III astrocytomas correlate with infiltrating CD8+ cells (2007) (63)
- FasL (CD95L/APO-1L) Resistance of Neurons Mediated by Phosphatidylinositol 3-Kinase-Akt/Protein Kinase B-Dependent Expression of Lifeguard/Neuronal Membrane Protein 35 (2005) (63)
- cIMPACT‐NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification (2017) (62)
- Chemoradiotherapy of newly diagnosed glioblastoma with intensified temozolomide. (2010) (62)
- Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas. (2005) (62)
- The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal. (2019) (62)
- Chemotherapy‐induced cell death in primary cerebellar granule neurons but not in astrocytes: in vitro paradigm of differential neurotoxicity (2004) (62)
- Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study (2018) (62)
- Radiochemotherapy of Malignant Glioma in Adults (2003) (62)
- Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome (2016) (61)
- Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial (2012) (61)
- PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma? (2020) (61)
- Diffusion-weighted MRI of spinal cord infarction (2004) (61)
- Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo (2016) (61)
- MicroRNA-138 promotes acquired alkylator resistance in glioblastoma by targeting the Bcl-2-interacting mediator BIM (2016) (60)
- Gemcitabine cytotoxicity of human malignant glioma cells: modulation by antioxidants, BCL-2 and dexamethasone. (1999) (60)
- Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial (2018) (60)
- Novel diagnostic and therapeutic approaches to malignant glioma. (2011) (60)
- NOA‐05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri (2011) (60)
- Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP. (1999) (59)
- Serum CD95 of relapsing remitting multiple sclerosis patients protects from CD95-mediated apoptosis (1998) (59)
- Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies. (2014) (59)
- Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis. (2004) (59)
- WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reflect a potential immune escape mechanism? (2007) (58)
- Adult medulloblastoma: prognostic factors and response to therapy at diagnosis and at relapse. (2005) (57)
- Synthesis of cytochrome c oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death (2012) (56)
- Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6‐hydroxydopamine‐induced apoptosis but not against the loss of their terminals (2001) (56)
- Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363. (2017) (56)
- Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): second interim analysis of a randomised, open-label, phase 3 study. (2021) (55)
- Identification of p21 as a target of cycloheximide-mediated facilitation of CD95-mediated apoptosis in human malignant glioma cells (2001) (55)
- BCL-2 Family Proteins Modulate Radiosensitivity in Human Malignant Glioma Cells (2004) (55)
- How we treat glioblastoma (2019) (55)
- Modulation of cerebral endothelial cell function by TGF-β in glioblastoma: VEGF-dependent angiogenesis versus endothelial mesenchymal transition (2015) (55)
- Death ligand/receptor-independent caspase activation mediates drug-induced cytotoxic cell death in human malignant glioma cells (1999) (55)
- Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression (2014) (54)
- Mouse mesenchymal stem cells suppress antigen-specific TH cell immunity independent of indoleamine 2,3-dioxygenase 1 (IDO1). (2010) (54)
- Low‐grade primary central nervous system lymphoma in immunocompetent patients (2005) (53)
- How we treat patients with leptomeningeal metastases (2019) (53)
- Chemotherapy sensitization of glioblastoma by focused ultrasound‐mediated delivery of therapeutic liposomes (2019) (53)
- Adjuvant therapy. (2020) (53)
- Isocitrate dehydrogenase mutations: A challenge to traditional views on the genesis and malignant progression of gliomas (2011) (53)
- A role for preirradiation PCV chemotherapy for oligodendroglial brain tumors (2000) (53)
- High‐throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification (2019) (52)
- P‐Glycoprotein and Multidrug Resistance‐associated Protein Mediate Specific Patterns of Multidrug Resistance in Malignant Glioma Cell Lines, but not in Primary Glioma Cells (2003) (52)
- Mutational patterns and regulatory networks in epigenetic subgroups of meningioma (2019) (52)
- Predicting outcome of epilepsy after meningioma resection. (2016) (52)
- Multimodal Imaging of Neural Progenitor Cell Fate in Rodents (2008) (51)
- MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1). (1999) (51)
- Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated (2021) (51)
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: Key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. (2013) (50)
- ATIM-03. ACT IV: AN INTERNATIONAL, DOUBLE-BLIND, PHASE 3 TRIAL OF RINDOPEPIMUT IN NEWLY DIAGNOSED, EGFRvIII-EXPRESSING GLIOBLASTOMA (2016) (50)
- NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma (2017) (50)
- Early whole brain radiotherapy in primary CNS lymphoma: negative impact on quality of life in the randomized G-PCNSL-SG1 trial (2017) (50)
- Glioblastoma quo vadis: Will migration and invasiveness reemerge as therapeutic targets? (2018) (50)
- Amino acid positron emission tomography to monitor chemotherapy response and predict seizure control and progression-free survival in WHO grade II gliomas. (2016) (50)
- BCL‐2‐induced glioma cell invasiveness depends on furin‐like proteases (2004) (50)
- NOA-08 randomized phase III trial of 1-week-on/1-week-off temozolomide versus involved-field radiotherapy in elderly (older than age 65) patients with newly diagnosed anaplastic astrocytoma or glioblastoma (Methusalem). (2010) (50)
- Multicenter pilot study of radiochemotherapy as first-line treatment for adults with medulloblastoma (NOA-07) (2018) (49)
- Gluteal Compartment Syndrome Due to Rhabdomyolysis After Heroin Abuse (1997) (49)
- Methylation of the p73 gene in gliomas (2002) (49)
- Corticosteroid use in neuro-oncology: an update. (2015) (49)
- Cerebrospinal fluid interleukins, immunoglobulins, and fibronectin in neuroborreliosis. (1991) (49)
- 3-Nitropropionic acid is an indirect excitotoxin to cultured cerebellar granule neurons. (1993) (49)
- Immunological challenges for peptide-based immunotherapy in glioblastoma. (2014) (49)
- A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. (2014) (49)
- Apoptosis in gliomas: molecular mechanisms and therapeutic implications. (2004) (49)
- Immunocytokines are a promising immunotherapeutic approach against glioblastoma (2020) (48)
- Radiochemotherapy of malignant glioma in adults. Clinical experiences. (2003) (48)
- Pirfenidone inhibits TGF-β expression in malignant glioma cells (2007) (48)
- ACNU-based chemotherapy for recurrent glioma in the temozolomide era (2008) (48)
- Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials (2011) (47)
- How lymphotoxic is dose-intensified temozolomide? The glioblastoma experience. (2005) (47)
- Intravenous and oral levetiracetam in patients with a suspected primary brain tumor and symptomatic seizures undergoing neurosurgery: the HELLO trial (2012) (47)
- Lymphatic outflow of cerebrospinal fluid is reduced in glioma (2019) (47)
- NIMG-56IMMUNOTHERAPY RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (iRANO): A REPORT OF THE RANO WORKING GROUP (2015) (47)
- Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma (2017) (47)
- Kinetics of tumor size and peritumoral brain edema before, during, and after systemic therapy in recurrent WHO grade II or III meningioma. (2016) (47)
- Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. (2012) (47)
- The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway (2016) (47)
- Glutamate receptor antagonists for neuroleptic malignant syndrome and akitetic hyperthermic Parkinsonian crisis (1993) (47)
- APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. (2011) (46)
- Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. (2012) (46)
- Antagonism of the mammalian target of rapamycin selectively mediates metabolic effects of epidermal growth factor receptor inhibition and protects human malignant glioma cells from hypoxia-induced cell death. (2009) (46)
- αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer (2014) (46)
- Modulation of TGF‐β activity by latent TGF‐β‐binding protein 1 in human malignant glioma cells (2009) (46)
- High-throughput proteomic analysis of FFPE tissue samples facilitates tumor stratification (2019) (46)
- Evidence-based recommendations on categories for extent of resection in diffuse glioma. (2021) (46)
- Modulation of MDR/MRP by wild-type and mutant p53. (2001) (46)
- A rationale for NMDA receptor antagonist therapy of the neuroleptic malignant syndrome. (1992) (45)
- BCL-xL: time-dependent dissociation between modulation of apoptosis and invasiveness in human malignant glioma cells (2006) (45)
- Insulin-like growth factor-1-mediated protection from neuronal apoptosis is linked to phosphorylation of the pro-apoptotic protein BAD but not to inhibition of cytochrome c translocation in rat cerebellar neurons (2000) (45)
- Contribution of PET imaging to radiotherapy planning and monitoring in glioma patients - a report of the PET/RANO group. (2021) (45)
- A tissue-based draft map of the murine MHC class I immunopeptidome (2018) (44)
- Hide-and-seek in the brain: a role for HLA-G mediating immune privilege for glioma cells. (2003) (44)
- Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern (2016) (44)
- Autocrine activation of the IFN signaling pathway may promote immune escape in glioblastoma (2017) (44)
- JC virus granule cell neuronopathy and GCN–IRIS under natalizumab treatment (2013) (44)
- Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation (2018) (44)
- Heat shock protein expression in human gliomas. (2000) (44)
- Adenovirus-mediated gene transfer of inhibitors of apoptosis protein delays apoptosis in cerebellar granule neurons. (1999) (44)
- Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases (2019) (44)
- Low molecular weight heparin for deep vein thrombosis in glioma patients (2002) (43)
- A characteristic ganglioside antibody pattern in the CSF of patients with amyotrophic lateral sclerosis. (1993) (43)
- Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochrome c release (2000) (43)
- DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment (2018) (42)
- Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. (2001) (42)
- Integrin inhibition promotes atypical anoikis in glioma cells (2014) (42)
- p27 modulates cell cycle progression and chemosensitivity in human malignant glioma. (1999) (42)
- Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. (2019) (42)
- Immune stimulatory effects of CD70 override CD70‐mediated immune cell apoptosis in rodent glioma models and confer long‐lasting antiglioma immunity in vivo (2006) (42)
- Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial. (2016) (42)
- CD95-Dependent T-Cell Killing by Glioma Cells Expressing CD95 Ligand: More on Tumor Immune Escape, the CD95 Counterattack, and the Immune Privilege of the Brain (1997) (42)
- CD95‐mediated Apoptosis of Human Glioma Cells: Modulation by Epidermal Growth Factor Receptor Activity (2002) (42)
- Barriers to Accrual and Enrollment in Brain Tumor Trials. (2019) (41)
- Temporal muscle thickness is an independent prognostic marker in patients with progressive glioblastoma: translational imaging analysis of the EORTC 26101 trial. (2019) (41)
- HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells (2012) (41)
- Macrophage Migration Inhibitory Factor Contributes to the Immune Escape of Ovarian Cancer by Down-Regulating NKG2D (2008) (41)
- Specific intensity imaging for glioblastoma and neural cell cultures with 5-aminolevulinic acid-derived protoporphyrin IX (2004) (41)
- Biological Role and Therapeutic Targeting of TGF-β3 in Glioblastoma (2017) (41)
- First-line therapy with temozolomide induces regression of primary CNS lymphoma. (2002) (41)
- Adult medulloblastoma (2005) (41)
- Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC Brain & RT Groups and NCIC Clinical Trials Group. (2004) (40)
- DNA methylation, transcriptome and genetic copy number signatures of diffuse cerebral WHO grade II/III gliomas resolve cancer heterogeneity and development (2019) (40)
- Primary glioblastoma cultures: can profiling of stem cell markers predict radiotherapy sensitivity? (2014) (40)
- Diagnosis and treatment patterns for patients with leptomeningeal metastasis from solid tumors across Europe (2016) (40)
- Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma. (2015) (40)
- Association of primary central nervous system lymphoma with long‐term azathioprine therapy for myasthenia gravis? (2000) (40)
- EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. (2019) (39)
- Apoptosis in gliomas, and its role in their current and future treatment. (2002) (39)
- Lysosomal ceramide mediates gemcitabine-induced death of glioma cells (2009) (39)
- Low grade ganglioglioma rapidly progressing to a WHO grade IV tumor showing malignant transformation in both astroglial and neuronal cell components (2007) (39)
- Suppression of proinvasive RGS4 by mTOR inhibition optimizes glioma treatment (2013) (38)
- A randomized, phase 3, open-label study of nivolumab versus temozolomide (TMZ) in combination with radiotherapy (RT) in adult patients (pts) with newly diagnosed, O-6-methylguanine DNA methyltransferase (MGMT)-unmethylated glioblastoma (GBM): CheckMate-498. (2016) (38)
- Tumor-associated edema in brain cancer patients: pathogenesis and management (2013) (38)
- Intravitreal daunomycin induces multidrug resistance in proliferative vitreoretinopathy. (1998) (38)
- Interferon-α enhances CD95L-induced apoptosis of human malignant glioma cells (1998) (38)
- Long-term control and partial remission after initial pseudoprogression of glioblastoma by anti-PD-1 treatment with nivolumab. (2016) (38)
- Adenoviral natural born killer gene therapy for malignant glioma. (2003) (38)
- Death receptor-mediated apoptosis in human malignant glioma cells: Modulation by the CD40/CD40L system (2005) (37)
- UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma (2005) (37)
- Identification of inhibitor‐of‐differentiation 2 (Id2) as a modulator of neuronal apoptosis (2002) (37)
- Thymosin β 4 gene silencing decreases stemness and invasiveness in glioblastoma. (2014) (37)
- Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825. (2013) (37)
- Control of glioma cell migration and invasiveness by GDF-15 (2016) (37)
- Malignant optic glioma – the spectrum of disease in a case series (2015) (37)
- Bag‐1 and Bcl‐2 Gene Transfer in Malignant Glioma: Modulation of Cell Cycle Regulation and Apoptosis (2000) (37)
- Complementary therapy use in patients with glioma (2010) (36)
- Tonic pupil, areflexia, and segmental anhidrosis: two additional cases of Ross syndrome and review of the literature (1992) (36)
- CSF and serum ganglioside antibody patterns in MS (1992) (36)
- Efficacy of Surgery and Further Treatment of Progressive Glioblastoma. (2015) (35)
- Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. (2020) (35)
- TGF‐β‐independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells (1999) (35)
- Temozolomide: a milestone in the pharmacotherapy of brain tumors. (2005) (35)
- The Role of Molecular Diagnostics in the Management of Patients with Gliomas (2016) (35)
- Primary central nervous system (CNS) lymphoma in immunocompetent patients (2002) (35)
- YAP1-fusions in pediatric NF2-wildtype meningioma (2019) (35)
- APO2L/TRAIL expression in human brain tumors (2000) (35)
- Neoadjuvant Gemcitabine/treosulfan Chemotherapy for Newly Diagnosed Glioblastoma (2004) (35)
- Hyperthermia enhanced chemosensitivity of human malignant glioma cells. (2000) (35)
- Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma. (2015) (35)
- T cell apoptosis induced by interleukin-2 deprivation or transforming growth factor-beta 2: modulation by the phosphatase inhibitors okadaic acid and calyculin A. (1995) (35)
- Diphenylhydantoin induces apoptotic cell death of cultured rat cerebellar granule neurons. (1995) (34)
- Use of metformin and outcome of patients with newly diagnosed glioblastoma: Pooled analysis (2020) (34)
- Iterative analysis of cerebrovascular reactivity dynamic response by temporal decomposition (2017) (34)
- CD133 expression is associated with small round blue cell tumour morphology in human CNS neoplasms . (2011) (34)
- Pirfenidone inhibits TGF-beta expression in malignant glioma cells. (2007) (34)
- End-of-life caregivers' perception of medical and psychological support during the final weeks of glioma patients: a questionnaire-based survey. (2013) (34)
- Light-Induced Apoptosis in the Rat Retina in Vivo (1995) (34)
- Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. (2019) (34)
- Targeting the Potassium Channel Kv1.3 Kills Glioblastoma Cells (2017) (34)
- Expression of the B7‐related molecule ICOSL by human glioma cells in vitro and in vivo (2003) (34)
- Niacinamide blocks 3-acetylpyridine toxicity of cerebellar granule cells in vitro (1992) (33)
- CD95 (Fas/APO-1) antibody-mediated apoptosis of human retinal pigment epithelial cells. (1995) (33)
- Onartuzumab plus bevacizumab versus placebo plus bevacizumab in recurrent glioblastoma (GBM): HGF and MGMT biomarker data. (2015) (33)
- The Innate Immune Response in the Central Nervous System and Its Role in Glioma Immune Surveillance (2004) (33)
- Working plan for the use of patient-reported outcome measures in adults with brain tumours: a Response Assessment in Neuro-Oncology (RANO) initiative. (2018) (33)
- Express and protect yourself: the potential role of HLA-G on muscle cells and in inflammatory myopathies. (2003) (32)
- Central nervous system Hodgkin’s lymphoma without systemic manifestation: case report and review of the literature (2000) (32)
- Retinal microglia: a new cell in idiopathic proliferative vitreoretinopathy? (1991) (32)
- Dual effect of glucocorticoids on apoptosis of human autoreactive and foreign antigen-specific T cells (2000) (32)
- Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice (2007) (32)
- Bcl-2, Bax and Bcl-x expression in neuronal apoptosis: a study of mutant weaver and lurcher mice (1998) (32)
- Potentiation of treosulfan toxicity by the glutathione-depleting agent buthionine sulfoximine in human malignant glioma cells: the role of bcl-2. (1998) (32)
- Vulnerability of invasive glioblastoma cells to lysosomal membrane destabilization (2019) (31)
- Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype (2020) (31)
- Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis (2017) (31)
- Combining standard clinical blood values for improving survival prediction in patients with newly diagnosed brain metastases—development and validation of the LabBM score (2017) (31)
- Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. (2010) (31)
- The topoisomerase I inhibitors, camptothecin and beta-lapachone, induce apoptosis of human retinal pigment epithelial cells. (1998) (31)
- Evidence for an active type of cell death with ultrastructural features distinct from apoptosis: The effects of 3-acetylpyridine neurotoxicity (1997) (31)
- The significance of complement in proliferative vitreoretinopathy. (1991) (31)
- Hysterical symptoms in ophthalmology (1989) (31)
- CODEL: Phase III study of RT, RT + Temozolomide (TMZ), or TMZ for newly-diagnosed 1p/19q Codeleted Oligodendroglioma. Analysis from the initial study design. (2020) (31)
- The natural HLA ligandome of glioblastoma stem-like cells: antigen discovery for T cell-based immunotherapy (2018) (31)
- Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma (2017) (30)
- Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities (2019) (30)
- Differentially regulated miRNAs as prognostic biomarkers in the blood of primary CNS lymphoma patients. (2015) (30)
- Caspase-dependent chemotherapy-induced death of glioma cells requires mitochondrial cytochrome c release. (2001) (30)
- p53 Enhances BAK and CD95 Expression in Human Malignant Glioma Cells but Does Not Enhance CD95L-Induced Apoptosis (1999) (30)
- Expression and putative functions of GDF-15, a member of the TGF-beta superfamily, in human glioma and glioblastoma cell lines. (2008) (30)
- Paraneoplastic Necrotizing Myopathy with a Mild Inflammatory Component: A Case Report and Review of the Literature (2010) (30)
- Glioma patient-reported outcome assessment in clinical care and research: a Response Assessment in Neuro-Oncology collaborative report. (2020) (30)
- Diagnostic value of WT1 in neuroepithelial tumours (2009) (30)
- Very‐late‐onset adrenoleukodystrophy (1992) (30)
- Potassium Deprivation-Induced Apoptosis of Cerebellar Granule Neurons: Cytochrome c Release in the Absence of Altered Expression of Bcl-2 Family Proteins (1998) (30)
- Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system. (2020) (29)
- New aspects of immunotherapy of leptomeningeal metastasis (1998) (29)
- C2-ceramide signaling in glioma cells: synergistic enhancement of CD95-mediated, caspase-dependent apoptosis (2001) (29)
- Osteopontin in cerebrospinal fluid as diagnostic biomarker for central nervous system lymphoma (2016) (29)
- A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network (2013) (29)
- Glioma gene therapy with soluble transforming growth factor-beta receptors II and III. (2008) (29)
- Mechanisms of Resistance of Human Glioma Cells to Apo2 Ligand/TNF-Related Apoptosis-Inducing Ligand (2006) (29)
- Accumulation of mutant p53(V143A) modulates the growth, clonogenicity, and radiochemosensitivity of malignant glioma cells independent of endogenous p53 status. (1999) (29)
- Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage. (2001) (29)
- Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma? (2012) (29)
- Identification of single nucleotide polymorphisms of the PI3K-AKT-mTOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. (2017) (29)
- Primary CNS lymphoma in the spinal cord: clinical manifestations may precede MRI delectability (2002) (29)
- Expression of the B 7-Related Molecule B 7-H 1 by Glioma Cells : A Potential Mechanism of Immune Paralysis 1 (2003) (29)
- Will integrin inhibitors have proangiogenic effects in the clinic? (2009) (29)
- Lovastatin and phenylacetate induce apoptosis, but not differentiation, in human malignant glioma cells (2001) (29)
- Humoral CSF parameters in the differential diagnosis of hematologic CNS neoplasia (1992) (28)
- Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group (2018) (28)
- Limited role for transforming growth factor-β pathway activation-mediated escape from VEGF inhibition in murine glioma models. (2016) (28)
- SNO and EANO practice guideline update: Anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. (2021) (28)
- Enzastaurin‐induced apoptosis in glioma cells is caspase‐dependent and inhibited by BCL‐XL (2008) (28)
- The HLA Ligand Atlas. A resource of natural HLA ligands presented on benign tissues (2019) (28)
- Immunological effects of chemotherapy and radiotherapy against brain tumors (2016) (28)
- Giant Cell Glioblastoma Is Associated With Altered Aurora B Expression and Concomitant p53 Mutation (2010) (27)
- The diagnostic value of cerebrospinal fluid pleocytosis and protein in the detection of lymphomatous meningitis in primary central nervous system lymphomas. (2006) (27)
- Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma? (2018) (27)
- Symptom clusters in newly diagnosed glioma patients: which symptom clusters are independently associated with functioning and global health status? (2019) (27)
- Clinical Neuropathology mini-review 6-2015: PD-L1: emerging biomarker in glioblastoma? (2015) (27)
- Synthesis and biological effects of NO in malignant glioma cells: modulation by cytokines including CD95L and TGF-β dexamethasone, and p53 gene transfer (1998) (27)
- Cellular stimulation via CD95 involves activation of phospho-inositide-3-kinase (1998) (27)
- Action of treosulfan in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis and human lymphocytes (2003) (27)
- Therapeutic Targeting of TGFβ Ligands in Glioblastoma Using Novel Antisense Oligonucleotides Reduces the Growth of Experimental Gliomas (2019) (27)
- Phase 0 and Window of Opportunity Clinical Trial Design in Neuro-Oncology: A RANO Review. (2020) (27)
- N-Methyl-D-asparate Receptor Agonists Decrease Protooncogene bcl-2 mRNA Expression in Cultured Rat Cerebellar Granule Neurons (1993) (27)
- Ocular manifestation of primary nervous system lymphoma: what can be expected from imaging? (2002) (27)
- Clinical Implications of Molecular Neuropathology and Biomarkers for Malignant Glioma (2012) (27)
- Primary central nervous system lymphomas (PCNSL): MRI response criteria revised (2005) (27)
- De novo erythropoietin receptor (EPO‐R) expression in human neoplastic glial cells decreases with grade of malignancy but is favourably associated with patient survival (2007) (26)
- Very late relapses in glioblastoma long-term survivors (2009) (26)
- Superiority of temozolomide over radiotherapy for elderly patients with RTK II methylation class, MGMT promoter-methylated malignant astrocytoma. (2020) (26)
- The variant methylenetetrahydrofolate reductase c.1298A>C (p.E429A) is associated with multiple sclerosis in a German case-control study (2010) (26)
- Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: Protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC). (2010) (26)
- Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. (2021) (26)
- 3-Nitropropionic Acid-Induced Ischemia Tolerance in the Rat Brain is Mediated by Reduced Metabolic Activity and Cerebral Blood Flow (2014) (26)
- Immunotherapy for glioblastoma: concepts and challenges. (2015) (26)
- Tumor cell dissemination triggers an intrathecal immune response in neoplastic meningitis (1992) (25)
- Copy number profiling across glioblastoma populations has implications for clinical trial design (2018) (25)
- Regeneration and tolerance factor: a novel mediator of glioblastoma-associated immunosuppression. (2006) (25)
- Amantadine and the glutamate hypothesis of schizophrenia Experiences in the treatment of neuroleptic malignant syndrome (2005) (25)
- Direct contact with perivascular tumor cells enhances integrin αvβ3 signaling and migration of endothelial cells (2016) (25)
- Chromosomal imbalances associated with response to chemotherapy and cytotoxic cytokines in human malignant glioma cell lines (2001) (25)
- Should biomarkers be used to design personalized medicine for the treatment of glioblastoma? (2010) (25)
- Clinically Isolated Neurosarcoidosis: A Recommended Diagnostic Path (2014) (25)
- Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas (2012) (25)
- CD95 expression and CD95-mediated apoptosis of T cells in multiple sclerosis No differences from normal individuals and no relation to HLA-DR2 (1998) (25)
- Alkylphosphocholine-induced glioma cell death is BCL-XL-sensitive, caspase-independent and characterized by massive cytoplasmic vacuole formation (2004) (25)
- Ceramide metabolism determines glioma cell resistance to chemotherapy (2009) (25)
- Expression of human tyrosine hydroxylase cDNA in invertebrate cells using a baculovirus vector. (1988) (25)
- An immunochemical quantitative analysis of the protein pattern in physiologic and pathologic vitreous (1991) (25)
- Treatment of Primary CNS Lymphoma (2013) (24)
- A new look at the role of p53 in leukemia cell sensitivity to chemotherapy (1997) (24)
- Pharmacotherapies for the treatment of glioblastoma – current evidence and perspectives (2016) (24)
- Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. (2019) (24)
- EGR‐1 is Regulated by N‐Methyl‐D‐Aspartate‐Receptor Stimulation and Associated with Patient Survival in Human High Grade Astrocytomas (2009) (24)
- Computer-assisted quantification of motile and invasive capabilities of cancer cells (2015) (24)
- Involvement of protein kinase Cdelta and extracellular signal-regulated kinase-2 in the suppression of microglial inducible nitric oxide synthase expression by N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast). (2003) (24)
- No induction of apoptosis by IFN-β in human antigen-specific T cells (2000) (24)
- Shaping the glioma immune microenvironment through tryptophan metabolism. (2012) (24)
- Drug-related problems and factors influencing acceptance of clinical pharmacologists` alerts in a large cohort of neurology inpatients. (2012) (24)
- Interleukin-33 in human gliomas: Expression and prognostic significance (2016) (24)
- Immediate Postoperative Radiotherapy or “Watch and Wait” in the Management of Adult Low-Grade Glioma? (2004) (24)
- Therapy of X-linked adrenoleukodystrophy (2008) (24)
- Neurosarcoidosis without systemic sarcoidosis (2005) (23)
- Appropriate end-points for right results in the age of antiangiogenic agents: future options for phase II trials in patients with recurrent glioblastoma. (2012) (23)
- TGF-β induces oncofetal fibronectin that, in turn, modulates TGF-β superfamily signaling in endothelial cells (2018) (23)
- Patterns of care in recurrent glioblastoma in Switzerland: a multicentre national approach based on diagnostic nodes (2016) (23)
- Chemosensitivity of human malignant glioma: modulation by p53 gene transfer (1998) (23)
- Erratum to: MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status (2013) (23)
- Expression and functional activity of osteoprotegerin in human malignant gliomas (2003) (23)
- Increased intrathecal synthesis of fibronectin in bacterial and carcinomatous meningitis (1990) (23)
- Prevalence of potential sports‐associated risk factors in Swiss amyotrophic lateral sclerosis patients (2017) (23)
- Sustained Efficacy of Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis Independent of Disease Activity and Disability at Baseline: Real-Life Data From a Swiss Cohort (2012) (23)
- Neurological complications of cancer immunotherapy. (2021) (23)
- Does clozapine cause neuroleptic malignant syndrome? (1993) (23)
- Pathogenesis and management of primary CNS lymphoma (2012) (23)
- Profound, durable and MGMT‐independent sensitivity of glioblastoma cells to cyclin‐dependent kinase inhibition (2019) (22)
- Intravitreal adenoviral gene transfer evokes an immune response in the retina that is directed against the heterologous lacZ transgene product but does not limit transgene expression (2001) (22)
- The role of integrins in glioma biology and anti-glioma therapies. (2011) (22)
- Supraagonistic, bispecific single‐chain antibody purified from the serum of cloned, transgenic cows induces T‐cell‐mediated killing of glioblastoma cells in vitro and in vivo (2005) (22)
- Treatment of active secondary progressive multiple sclerosis with treosulfan (2007) (22)
- Inhibition of experimental rat glioma growth by decorin gene transfer is associated with decreased microglial infiltration (1999) (22)
- Genetic variants of folate and methionine metabolism and PCNSL incidence in a German patient population (2010) (22)
- N‐[3,4‐dimethoxycinnamoyl]‐anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon‐γ (IFN‐γ) (2001) (22)
- Management of neoplastic meningitis. (2015) (22)
- Optimizing eligibility criteria and clinical trial conduct to enhance clinical trial participation for primary brain tumor patients. (2020) (22)
- VEGF-dependent induction of CD62E on endothelial cells mediates glioma tropism of adult haematopoietic progenitor cells. (2008) (22)
- Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up. (2020) (22)
- Chemotherapy for intracranial ependymoma in adults (2016) (21)
- Recurrent gastrointestinal tract bleeding secondary to jejunal gastric heterotopia. (2005) (21)
- Developmental and genetic regulation of programmed neuronal death. (1997) (21)
- Geriatric neuro-oncology: from mythology to biology. (2011) (21)
- Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). Conclusive results of a randomized phase III trial by the EORTC (2005) (21)
- Neuro-oncology, a decade of temozolomide and beyond (2010) (21)
- Clinical management and outcome of histologically verified adult brainstem gliomas in Switzerland: a retrospective analysis of 21 patients (2014) (21)
- Stem cell-mediated gene therapies for malignant gliomas: a promising targeted therapeutic approach? (2011) (21)
- Antioxidants specifically inhibit cisplatin cytotoxicity of human malignant glioma cells. (1998) (21)
- Transcriptional control of O6‐methylguanine DNA methyltransferase expression and temozolomide resistance in glioblastoma (2018) (21)
- Genetic variants of methionine metabolism and X-ALD phenotype generation: results of a new study sample (2009) (21)
- Altered intraoperative cerebrovascular reactivity in brain areas of high-grade glioma recurrence. (2016) (21)
- Non-IDH1-R132H IDH1/2 mutations are associated with increased DNA methylation and improved survival in astrocytomas, compared to IDH1-R132H mutations (2021) (21)
- The Time of Maximum Post-Ischemic Hyperperfusion Indicates Infarct Growth Following Transient Experimental Ischemia (2013) (21)
- Interferon-alpha enhances CD95L-induced apoptosis of human malignant glioma cells. (1998) (21)
- Neuro-oncology in 2013: Improving outcome in newly diagnosed malignant glioma (2014) (20)
- Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trial (2015) (20)
- Anticoagulation for radiation-induced neurotoxicity revisited (2008) (20)
- The costs of disorders of the brain in Switzerland: an update from the European Brain Council Study for 2010. (2013) (20)
- The pathogenesis of vitreoretinal proliferation and traction: a working hypothesis. (1990) (20)
- Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines. (1999) (20)
- Glioblastoma in the elderly: making sense of the evidence. (2016) (20)
- CAMTA 1 is a novel tumour suppressor regulated by miR-9 / 9 * in glioblastoma stem cells (2011) (20)
- Evidence for a constitutive, verapamil-sensitive, non-P-glycoprotein multidrug resistance phenotype in malignant glioma that is unaltered by radiochemotherapy in vivo (2000) (20)
- The significance of fibronectin in vitreoretinal pathology (1988) (20)
- SC68896, a Novel Small Molecule Proteasome Inhibitor, Exerts Antiglioma Activity In vitro and In vivo (2009) (20)
- Proteasome inhibition for the treatment of glioblastoma (2020) (20)
- MK-801 and memantine protect cultured neurons from glutamate toxicity induced by glutamate carboxypeptidase-mediated cleavage of methotrexate. (1993) (20)
- Cutting Edge: ERK1 Mediates the Autocrine Positive Feedback Loop of TGF-β and Furin in Glioma-Initiating Cells (2017) (20)
- The added value of health-related quality of life as a prognostic indicator of overall survival and progression-free survival in glioma patients: a meta-analysis based on individual patient data from randomised controlled trials. (2019) (20)
- How Stemlike Are Sphere Cultures From Long-term Cancer Cell Lines? Lessons From Mouse Glioma Models (2014) (19)
- Defective p53 antiangiogenic signaling in glioblastoma. (2010) (19)
- Do host factors determine long-term survival in glioblastoma? A genome/transcriptome profiling study by the German Glioma Network. (2014) (19)
- Plasminogen in proliferative vitreoretinal disorders (1997) (19)
- The presence of oligoclonal IgG bands in human CSF during the course of neurological diseases (2014) (19)
- Management of Elderly Patients with Glioblastoma (2017) (19)
- Inhibition of drug-induced DNA fragmentation, but not cell death, of glioma cells by non-caspase protease inhibitors. (1999) (19)
- Defining EGFR amplification status for clinical trial inclusion (2019) (19)
- Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion. (2019) (19)
- Hyper-N-glycosylated SAMD14 and neurabin-I as driver autoantigens of primary central nervous system lymphoma. (2018) (19)
- High-dose praziquantel therapy for cerebral sparganosis (2013) (19)
- Data Sets for the Reporting of Tumors of the Central Nervous System. (2019) (18)
- Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142). (2011) (18)
- Predisposing and precipitating factors for delirium in neurology: a prospective cohort study of 1487 patients (2019) (18)
- Maturation‐dependent Modulation of Apoptosis in Cultured Cerebellar Granule Neurons by Cytokines and Neurotrophins (1996) (18)
- NDRG1 prognosticates the natural course of disease in WHO grade II glioma (2014) (18)
- Diffuse gliomas exhibit whole brain impaired cerebrovascular reactivity. (2018) (18)
- Anaplastic Oligodendroglioma: A New Treatment Paradigm and Current Controversies (2013) (18)
- Predisposing and precipitating risk factors for delirium in palliative care patients (2019) (18)
- How we treat patients with brain tumour during the COVID-19 pandemic (2019) (18)
- Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma (2021) (17)
- NMDA receptor-mediated excitoprotection of cultured cerebellar granule neurons fails to alter glutamate-induced expression of c-fos and c-jun mRNAs. (1994) (17)
- Deep-learning-based synthesis of post-contrast T1-weighted MRI for tumour response assessment in neuro-oncology: a multicentre, retrospective cohort study. (2021) (17)
- Risk factors for the development of epilepsy in patients with brain metastasis. (2019) (17)
- Altered expression of calcium‐ and apoptosis‐regulating proteins in multiple system atrophy purkinje cells (2000) (17)
- Genomic profiling reveals distinctive molecular relapse patterns in IDH1/2 wild‐type glioblastoma (2014) (17)
- March 2003: a 41 -year-old female with a solitary lesion in the liver. (2003) (17)
- Bevacizumab versus alkylating chemotherapy in recurrent glioblastoma (2019) (17)
- [Current status of biochemical hypotheses in the pathogenesis of schizophrenia]. (1994) (17)
- Evaluation of drug interactions and dosing in 484 neurological inpatients using clinical decision support software and an extended operational interaction classification system (Zurich Interaction System) (2011) (17)
- Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells (2016) (17)
- p53 and its family members – reporter genes may not see the difference (2004) (17)
- Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Optic Neuritis (2019) (17)
- Trabectedin for recurrent WHO grade II or III meningioma: A randomized phase II study of the EORTC Brain Tumor Group (EORTC-1320-BTG). (2019) (17)
- Epidermal growth factor receptor and ligand family expression and activity in glioblastoma (2018) (17)
- Influence of gangliosides on experimental allergic neuritis (1992) (17)
- Prognostic relevance of miRNA-155 methylation in anaplastic glioma (2016) (17)
- Novel TIE‐2 inhibitor BAY‐826 displays in vivo efficacy in experimental syngeneic murine glioma models (2017) (17)
- NF-κB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells (2003) (16)
- Antiangiogenic Treatment for Multiple CNS Hemangioblastomas (2012) (16)
- Opercular syndrome without opercular lesions: Foix-Chavany-Marie syndrome in progressive supranuclear motor system degeneration (2005) (16)
- Glioma tropism of lentivirally transduced hematopoietic progenitor cells. (2010) (16)
- Classification and management of anaplastic gliomas (2009) (16)
- Diagnostic value of 18F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site. (2018) (16)
- Failure of taxol-based combination chemotherapy for malignant glioma cannot be overcome by G2/M checkpoint abrogators or altering the p53 status (1999) (16)
- Death receptor-independent cytochrome c release and caspase activation mediate thymidine kinase plus ganciclovir-mediated cytotoxicity in LN-18 and LN-229 human malignant glioma cells (2001) (16)
- The role of caspases 9 and 9-short (9S) in death ligand- and drug-induced apoptosis in human astrocytoma cells. (2002) (16)
- Etoposide/carboplatin chemotherapy for the treatment of metastatic myxomatous cerebral aneurysms (2014) (16)
- Letter to the Editor: “The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline” [J Neurooncol 2014; 118:435–460] (2014) (16)
- Randomized phase III study of sequential radiochemotherapy of oligoastrocytic tumors of WHO-grade III with PCV or temozolomide: NOA-04 (2008) (16)
- Subacute cerebellar ataxia following respiratory symptoms of COVID-19: a case report (2021) (16)
- Immunology of brain tumors. (2012) (16)
- Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression. (1998) (16)
- CHD7 promotes glioblastoma cell motility and invasiveness through transcriptional modulation of an invasion signature (2019) (15)
- Closed-loop cavitation control for focused ultrasound-mediated blood–brain barrier opening by long-circulating microbubbles (2019) (15)
- Voluntary facial palsy with a pontine lesion. (1996) (15)
- Does cilengitide deserve another chance?-Authors' reply. (2014) (15)
- Questions regarding the optimal use of bevacizumab in glioblastoma: a moving target. (2014) (15)
- Retroviral BAX gene transfer fails to sensitize malignant glioma cells to CD95L‐induced apoptosis and cancer chemotherapy (1998) (15)
- MIP-1α Antagonizes the Effect of a GM-CSF-Enhanced Subcutaneous Vaccine in a Mouse Glioma Model (2004) (15)
- Response assessment of meningioma: 1D, 2D, and volumetric criteria for treatment response and tumor progression (2018) (15)
- Glutathione S-transferase and drug sensitivity in malignant glioma (2000) (15)
- [Pathophysiology and therapy of malignant neuroleptic syndrome]. (1992) (15)
- Mechanisms of apoptosis in central nervous system tumors: Application to theory (2002) (15)
- Glioma Cell Death Induced by Irradiation or Alkylating Agent Chemotherapy Is Independent of the Intrinsic Ceramide Pathway (2013) (15)
- Immunochemotherapy of malignant glioma: synergistic activity of CD95 ligand and chemotherapeutics (1997) (15)
- Expression and upregulation of microtubule-associated protein 1B in cultured retinal pigment epithelial cells. (1997) (15)
- Endonucleolytic DNA fragmentation is not required for apoptosis of cultured rat cerebellar granule neurons (1998) (15)
- Vitronectin and proliferative intraocular disorders. I. A colocalisation study of the serum spreading factor, vitronectin, and fibronectin in traction membranes from patients with proliferative vitreoretinopathy (1991) (15)
- Pseudoprogression: fact or wishful thinking in neuro-oncology? (2018) (15)
- Chemotherapy primes malignant glioma cells for CD95 ligand-induced apoptosis up-stream of caspase 3 activation. (1998) (15)
- Procarbazine and CCNU as Initial Treatment in Gliomatosis Cerebri (2008) (15)
- Adenoviral (Full-Length) Apo2L/TRAIL Gene Transfer is an Ineffective Treatment Strategy for Malignant Glioma (2004) (14)
- Interferon-β Modulates the Innate Immune Response against Glioblastoma Initiating Cells (2015) (14)
- Amyotrophic lateral sclerosis after embolization of cerebral arterioveneous malformations (2014) (14)
- Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells (1998) (14)
- Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma. (2020) (14)
- Immunochemical analysis of periretinal membranes. Review and outlook. (1989) (14)
- Hypericin: a promising fluorescence marker for differentiating between glioblastoma and neurons in vitro. (2005) (14)
- The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis (2003) (14)
- No induction of apoptosis by IFN-beta in human antigen-specific T cells. (2000) (14)
- The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma (2021) (14)
- Minocycline-induced benign intracranial hypertension (1997) (14)
- Lyell syndrome and lethal catatonia: a case for ECT. (1992) (14)
- Intracranial Metastatic Esthesioneuroblastoma Responsive to Temozolomide (2004) (14)
- Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial. (2020) (14)
- Primary central nervous system tumors: pathogenesis and therapy. (2012) (14)
- Determining medical decision-making capacity in brain tumor patients: why and how? (2020) (13)
- Thrombospondin: A New Attachment Protein in Preretinal Traction Membranes (1992) (13)
- Primary anaplastic ganglioglioma with a small-cell glioblastoma component. (2008) (13)
- Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach (2013) (13)
- The effects of basic fibroblast growth factor on bovine retinal pigment epithelium in vitro. (1992) (13)
- A series of patients with subpial hemorrhage: Clinical manifestation, neuroradiological presentation and therapeutic implications (2008) (13)
- Contraceptive drugs mitigate experimental stroke-induced brain injury (2018) (13)
- Primary Tumors of the Central and Peripheral Nervous System (2003) (13)
- Updated results of the INTELLANCE 2/EORTC trial 1410 randomized phase II study on Depatux –M alone, Depatux-M in combination with temozolomide (TMZ) and either TMZ or lomustine (LOM) in recurrent EGFR amplified glioblastoma (NCT02343406). (2018) (13)
- N-[3,4-dimethoxycinnamoyl]-anthranilic acid (tranilast) suppresses microglial inducible nitric oxide synthase (iNOS) expression and activity induced by interferon-gamma (IFN-gamma). (2001) (13)
- ATPS-73BIOLOGICAL ACTIVITY OF TUMOR-TREATING FIELDS (TTFIELDS) IN GLIOMA MODELS IN A PRECLINICAL SETTING (2015) (13)
- Ocular myasthenia gravis: response to long term immunosuppressive treatment (1997) (13)
- Antitumor Activity of DLX1008, an Anti-VEGFA Antibody Fragment with Low Picomolar Affinity, in Human Glioma Models (2018) (13)
- Human Malignant Glioma Cell Lines are Refractory to Retinoic Acid-Mediated Differentiation and Sensitization to Apoptosis1 (2000) (13)
- Similar protective effects of BQ-123 and erythropoietin on survival of neural cells and generation of neurons upon hypoxic injury. (2005) (13)
- Current State of Immune-Based Therapies for Glioblastoma. (2016) (12)
- APO010, a synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cells. (2013) (12)
- Assessing the MGMT status in glioblastoma: one step forward, two steps back? (2013) (12)
- CD 95 expression in traumatic proliferative vitreoretinopathy: a target for the induction of apoptosis. (1996) (12)
- Demonstration of mononuclear phagocytes in a human epiretinal membrane using a monoclonal anti-human macrophage antibody (2005) (12)
- Angiogenesis in glioblastoma: just another moving target? (2010) (12)
- Progressive multifocal leukoencephalopathy (2003) (12)
- ACTR-39. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE (2019) (12)
- Iron-binding proteins in the human vitreous: lactoferrin and transferrin in health and in proliferative intraocular disorders. (1990) (12)
- Cytotoxic effects of daunomycin on retinal pigment epithelium in vitro (2005) (12)
- Neurocognitive functioning and health-related quality of life in adult medulloblastoma patients: long-term outcomes of the NOA-07 study (2020) (12)
- Genetic variants of homocysteine metabolism and multiple sclerosis: A case–control study (2014) (12)
- LTBK-04 FIRST RESULTS OF THE RANDOMIZED PHASE II STUDY ON DEPATUX –M ALONE, DEPATUX-M IN COMBINATION WITH TEMOZOLOMIDE AND EITHER TEMOZOLOMIDE OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA: FIRST REPORT FROM INTELLANCE 2/EORTC TRIAL 1410 (2017) (12)
- Rare ADAR and RNASEH2B variants and a type I interferon signature in glioma and prostate carcinoma risk and tumorigenesis (2017) (12)
- Immunotherapy of Brain Cancer (2016) (12)
- MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial (2020) (11)
- Boswellic acid activity against glioblastoma stem-like cells. (2016) (11)
- Temporal Muscle Thickness as a Prognostic Marker in Patients with Newly Diagnosed Glioblastoma: Translational Imaging Analysis of the CENTRIC EORTC 26071–22072 and CORE Trials (2021) (11)
- Treosulfan Chemotherapy for Recurrent Malignant Glioma (2000) (11)
- A randomized phase 2, single-blind study of temozolomide (TMZ) and radiotherapy (RT) combined with nivolumab or placebo (PBO) in newly diagnosed adult patients (pts) with tumor O6-methylguanine DNA methyltransferase (MGMT)-methylated glioblastoma (GBM)—CheckMate-548 (2016) (11)
- Anticonvulsive effect of anterior thalamic deep brain stimulation in super-refractory status epilepticus crucially depends on active stimulation zone—A single case observation (2019) (11)
- The legend of cytomegalovirus and glioblastoma lives on. (2014) (11)
- Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial (2021) (11)
- Post-operative cardiovascular complications and time to recurrence in meningioma patients treated with versus without pre-operative embolization: a retrospective cohort study of 741 patients (2018) (11)
- Ganglioside antibodies in schizophrenia and major depression (1992) (11)
- The ERGO trial: A pilot study of a ketogenic diet in patients with recurrent glioblastoma. (2010) (11)
- Does Neuronal Activity Promote Glioma Progression? (2020) (11)
- Leukoencephalopathy after prophylactic whole-brain irradiation with or without hippocampal sparing: a longitudinal magnetic resonance imaging analysis. (2019) (11)
- Progressive multifocal leukoencephalopathy: cidofovir therapy in three patients with underlying hematological disease. (2003) (11)
- The mTOR target NDRG 1 confers MGMT-dependent resistance to alkylating chemotherapy (2017) (11)
- Hypoxia Enhances the Antiglioma Cytotoxicity of B10, a Glycosylated Derivative of Betulinic Acid (2014) (11)
- Expression of integrins αvβ3 and αvβ5 and their ligands in primary and secondary central nervous system neoplasms. (2013) (11)
- FOCAD loss impacts microtubule assembly, G2/M progression and patient survival in astrocytic gliomas (2019) (11)
- Differential expression of the tumor suppressor A-kinase anchor protein 12 in human diffuse and pilocytic astrocytomas is regulated by promoter methylation. (2013) (11)
- Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05) (2011) (11)
- Immunochemical studies of epiretinal membranes using APAAP complexes: Evidence for macrophage involvement in traumatic proliferative vitreoretinopathy (2004) (11)
- Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase 2 study of the EORTC Brain Tumor Group (EORTC-1320-BTG). (2021) (11)
- Predicting responsiveness to fampridine in gait‐impaired patients with multiple sclerosis (2018) (11)
- Assessment of Karnofsky (KPS) and WHO (WHO-PS) performance scores in brain tumour patients: the role of clinician bias (2020) (10)
- Chromosomal imbalances associated with response to chemotherapy and cytotoxic cytokines in human malignant glioma cell lines. (2001) (10)
- The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy. (2021) (10)
- Synergy of CD95 ligand and teniposide: no role of cleavable complex formation and enhanced CD95 expression. (1998) (10)
- Dose-intensified rechallenge with temozolomide: One week on/one week off versus 3 weeks on/one week off in patients with progressive or recurrent glioblastoma. (2010) (10)
- Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. (2018) (10)
- Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma dependends on MMP9. (2019) (10)
- PCTAIRE3: a putative mediator of growth arrest and death induced by CTS-1, a dominant-positive p53-derived synthetic tumor suppressor, in human malignant glioma cells (2006) (10)
- OMRT-3. Longitudinal analysis of diffuse glioma reveals cell state dynamics at recurrence associated with changes in genetics and the microenvironment (2021) (10)
- Are we ready for a randomized trial of valproic acid in newly diagnosed glioblastoma? (2013) (10)
- Modulation of neuronal activity by the endogenous pentapeptide QYNAD (2003) (10)
- Human Cancer Biology Costimulatory Protein 4 IgB 7 H 3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness (2011) (10)
- Postpartum psychosis and mastitis: a new indication for clozapine? (1991) (10)
- CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548 (2021) (10)
- The significance of vitronectin in proliferative diabetic retinopathy (1994) (10)
- The thermolabile variant of 5,10-methylenetetrahydrofolate reductase is a possible risk factor for amyotrophic lateral sclerosis (2011) (10)
- Nachstarprävention durch endokapsuläre Daunomycinapplikation (1990) (10)
- Complementary and alternative medicine use by glioma patients in Switzerland. (2018) (10)
- Elevated CSF lactoferrin in superficial siderosis of the central nervous system (1999) (10)
- TGF-b and metalloproteinases differentially suppress NKG 2 D ligand surface expression on malignant glioma cells (2006) (10)
- CD95 ligand-induced apoptosis of human medulloblastoma cells. (1998) (10)
- Methylome analyses of three glioblastoma cohorts reveal chemotherapy sensitivity markers within DDR genes (2020) (10)
- Addition of lomustine for bevacizumab-refractory recurrent glioblastoma (2014) (9)
- Romiplostim for temozolomide-induced thrombocytopenia in glioblastoma (2019) (9)
- Malignant astrocytoma in elderly patients: where do we stand? (2013) (9)
- Enzastaurin (ENZ) before and concomitant with radiation therapy (RTX), followed by ENZ maintenance therapy in patients with newly diagnosed glioblastoma (GBM) without hypermethylation of the O6-methylguanyl DNA-methyltransferase (MGMT) promoter: A multicenter, open-label, uncontrolled phase II study (2011) (9)
- Are we ready to demystify age in glioblastoma? Or does older age matter in glioblastoma? (2011) (9)
- Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma (2015) (9)
- The vanishing role of whole brain radiotherapy for primary central nervous system lymphoma. (2014) (9)
- Relapse of primary CNS lymphoma after more than 10 years in complete remission (2005) (9)
- Patient selection and remission rates with the current practice of electroconvulsive therapy in Germany. (1995) (9)
- Topotecan-based combination chemotherapy for human malignant glioma. (1999) (9)
- NF-kappaB-independent actions of sulfasalazine dissociate the CD95L- and Apo2L/TRAIL-dependent death signaling pathways in human malignant glioma cells. (2003) (9)
- Survival of brain tumour patients with epilepsy. (2021) (9)
- Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma (2020) (9)
- Sex-specific aspects of epidemiology, molecular genetics and outcome: primary brain tumours (2020) (9)
- Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas (2017) (9)
- PAX2 is an antiapoptotic molecule with deregulated expression in medulloblastoma. (2012) (9)
- TGF-beta-independent induction of immunogenicity by decorin gene transfer in human malignant glioma cells. (1999) (9)
- Where does O6‐methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma? (2018) (9)
- MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial. (2014) (9)
- Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma (2021) (9)
- Depatuxizumab Mafodotin (ABT-414)-induced Glioblastoma Cell Death Requires EGFR Overexpression, but not EGFRY1068 Phosphorylation (2020) (9)
- Apoptotic cell death in proliferative vitreoretinopathy. (1996) (9)
- Monitoring the glioma tropism of bone marrow-derived progenitor cells by 2-photon laser scanning microscopy and positron emission tomography. (2012) (9)
- Bintrafusp alfa (M7824), a bifunctional fusion protein targeting TGF-β and PD-L1: results from a phase I expansion cohort in patients with recurrent glioblastoma (2021) (9)
- Preparation of PEGylated liposomes incorporating lipophilic lomeguatrib derivatives for the sensitization of chemo-resistant gliomas. (2018) (9)
- Prognostic impact of meningeal dissemination in primary CNS lymphoma (PCNSL): experience from the G-PCNSL-SG1 trial. (2012) (9)
- [Prevention of secondary cataract by intracapsular administration of the antimitotic daunomycin]. (1990) (9)
- The effect of MTHFR c.677C>T on plasma homocysteine levels depends on health, age and smoking. (2009) (9)
- [Thrombospondin and its importance in proliferative retinal diseases]. (1991) (9)
- Immunological abnormalities in the tears of multiple sclerosis patients (1992) (8)
- N-methyl-D-aspartate receptor agonists decrease protooncogene bcl-2 mRNA expression in cultured rat cerebellar granule neurons. (1993) (8)
- Chemotherapy for low-grade gliomas: when? how? how long? (2010) (8)
- Transferrin and transferrin receptor expression in intraocular proliferative disease. APAAP-immunolabeling of retinal membranes and ELISA for vitreal transferrin (2005) (8)
- End-of-life care for glioma patients; the caregivers’ perspective (2020) (8)
- Evaluation of daunomycin toxicity on lens epithelium in vitro (2004) (8)
- Antiepileptic drugs and vitamin B6 plasma levels in adult patients (2012) (8)
- Hypothyroidism correlates with favourable survival prognosis in patients with brain metastatic cancer. (2020) (8)
- Characterization of CD95 ligand (CD95L)-induced apoptosis in human tenon fibroblasts. (2002) (8)
- Automatic-voluntary dissociation: An unusual facial paresis in a patient with probable multiple sclerosis (2005) (8)
- CANCER RISK AMONG PATIENTS WITH MULTIPLE SCLEROSIS AND THEIR PARENTS. Authors' reply (2010) (8)
- A vasculature-centric approach to developing novel treatment options for glioblastoma (2021) (8)
- [Erratum] ERGO: A pilot study of ketogenic diet in recurrent glioblastoma (2014) (8)
- Prognostic factors for response and survival in primary central nervous system lymphoma (PCNSL) from a randomized phase III trial (G-PCNSL-SG-1). (2011) (8)
- Crossed Cerebellar Diaschisis in Patients with Diffuse Glioma Is Associated with Impaired Supratentorial Cerebrovascular Reactivity and Worse Clinical Outcome (2020) (8)
- Vitronectin and proliferative intraocular disorders. I. A colocalisation study of the serum spreading factor, vitronectin, and fibronectin in traction membranes from patients with proliferative vitreoretinopathy (1991) (8)
- Acute transverse myelitis associated with coxiella burnetii infection (2002) (8)
- [Proliferative vitreoretinopathy: new discoveries in pathophysiology and therapy]. (1990) (8)
- Neuropathological Characteristics of Progression after Prolonged Response to Bevacizumab in Multifocal Hemangioblastoma (2014) (8)
- Temozolomide and MGMT forever? (2010) (8)
- Beyond the World Health Organization classification of central nervous system tumors 2016: what are the new developments for gliomas from a clinician's perspective? (2020) (8)
- GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma. (2020) (8)
- Identification by suppression subtractive hybridization of p21 as a radio-inducible gene in human glioma cells. (2001) (8)
- [New therapeutic possibilities with low-affinity NMDA receptor antagonists]. (1996) (8)
- CD133 expression is associated with small round blue cell tumour morphology in human central nervous system neoplasms (2011) (8)
- Lumbar disk prolapse: response to mechanical physiotherapy in the absence of changes in magnetic resonance imaging. Report of 11 cases. (2008) (7)
- Irradiation induced clonogenic cell death of human malignant glioma cells does not require CD95/CD95L interactions. (1999) (7)
- Systematic review on the use of patient-reported outcome measures in brain tumor studies: part of the Response Assessment in Neuro-Oncology Patient-Reported Outcome (RANO-PRO) initiative. (2021) (7)
- Complementary and alternative medicine use in glioma patients in France (2019) (7)
- N-methyl-D-aspartate antagonists, schizophrenia, and neuroleptic malignant syndrome. (1992) (7)
- Hypoxia sensitizes human malignant glioma cells towards CD95L‐induced cell death (2005) (7)
- Management of diffusely infiltrating glioma in the elderly (2015) (7)
- Socioeconomic burden and quality of life in meningioma patients (2020) (7)
- Humoral immune response to p53 in malignant glioma (1998) (7)
- Bevacizumab failure in glioblastomas. (2012) (7)
- Neurology—the next 10 years (2015) (7)
- Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial. (2020) (7)
- Neurocognitive function: an emerging surrogate endpoint for neuro-oncology trials. (2011) (7)
- [Differential neuroleptic treatment of schizophrenic psychoses in puerperium: advantages of the atypical neuroleptic clozapine]. (1992) (7)
- Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23 (2021) (7)
- Interferon-β sensitizes human glioblastoma cells to the cyclin-dependent kinase inhibitor, TG02 (2020) (7)
- The reduced unsubstituted pteroate moiety is required for folate toxicity of cultured cerebellar granule neurons. (1994) (7)
- Telomerase reverse transcriptase promoter mutation- and O6-methylguanine DNA methyltransferase promoter methylation-mediated sensitivity to temozolomide in isocitrate dehydrogenase-wild-type glioblastoma: is there a link? (2021) (7)
- Ganglioside antibodies: a lack of diagnostic specificity and clinical utility? (1992) (7)
- Temozolomide and radiotherapy versus radiotherapy alone in patients with glioblastoma, IDH-wildtype: post-hoc analysis of the EORTC randomized phase 3 CATNON trial. (2022) (7)
- The management of lomustine overdose in malignant glioma patients. (2014) (7)
- Synergistic growth inhibition mediated by dual PI3K/mTOR pathway targeting and genetic or direct pharmacological AKT inhibition in human glioblastoma models (2020) (7)
- Electroconvulsive therapy in a geriatric patient with multiple bone fractures and generalized plasmocytoma. (1992) (7)
- Characterization of daunorubicin-induced apoptosis in retinal pigment epithelial cells: modulation by CD95L. (2003) (7)
- Imaging necrosis during treatment is associated with worse survival in EORTC 26101 study (2019) (7)
- Impact of MGMT promoter methylation in glioblastoma of the elderly. (2011) (7)
- EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma. (2019) (7)
- Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma (2021) (7)
- Tumor-treating fields: time for demystification. (2018) (7)
- Soluble CD95 (Fas/APO-1) in Malignant Glioma: (No) Implications for CD95-based Immunotherapy? (1998) (6)
- Hypermetabolism and impaired cerebrovascular reactivity beyond the standard MRI-identified tumor border indicate diffuse glioma extended tissue infiltration (2021) (6)
- Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p (2018) (6)
- Bevacizumab--news from the fast lane? (2008) (6)
- Patients with Primary Central Nervous System Lymphoma Not Eligible for Clinical Trials: Prognostic Factors, Treatment and Outcome (2021) (6)
- Approval of new drugs for glioblastoma. (2009) (6)
- MRI white matter hyperintensity in neuroleptic malignant syndrome (NMS)—a clue to pathogenesis? (2005) (6)
- Reciprocal modulation of Aβ42 aggregation by copper and homocysteine (2014) (6)
- One week on/one week off regimen of temozolomide: Phase II trial in recurrent glioma (2007) (6)
- Cetuximab induced aseptic meningitis (2015) (6)
- Comparative evaluation of the drug interaction screening programs MediQ and ID PHARMA CHECK in neurological inpatients (2012) (6)
- EGFR gene amplification and variant III (EGFRvIII) mutation in primary and recurrent glioblastoma. (2016) (6)
- [Immunohistochemical findings in proliferative retinal diseases--on the significance of fibronectin, macrophages and transferrin]. (1989) (6)
- An Enzyme- and Serum-free Neural Stem Cell Culture Model for EMT Investigation Suited for Drug Discovery. (2016) (6)
- Meeting Report: Primary Central Nervous System Lymphoma: Standards Of Care And Future Perspectives (2005) (6)
- CCNU overdose during PCV chemotherapy for anaplastic astrocytoma (1998) (6)
- Endoglin and TGF-β signaling in glioblastoma (2021) (6)
- Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma. (2020) (6)
- [Role of macrophages and fibronectin in vitreoretinal proliferation]. (1988) (6)
- [Idiopathic proliferative vitreoretinopathy. Activation of microglial cells as the deciding factor]. (1992) (6)
- p53 Accumulation Promotes Dephosphorylation and Proteolytic Cleavage of Retinoblastoma Protein in Human Malignant Glioma Cells (1997) (6)
- Prognostic factors for chemotherapy-related toxicity in primary central nervous system lymphoma (PCNSL) treated with high-dose methotrexate (HDMTX) with or without ifosfamide: Results from a German phase III trial (G-PCNSL-SG-1). (2011) (6)
- MLTI-19. VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH BRAIN METASTASES: THE PICOS SCORE (2019) (6)
- Thymosin beta 4 gene silencing decreases stemness and invasiveness in glioblastoma (2014) (6)
- 31 Temozolomide (TMZ) targets only glioblastoma with a silenced MGMT-gene. Results of a translational companion study to EORTC 26981/NCIC CE.3 of radiotherapy ± TMZ (2004) (6)
- Radiochemotherapy for Brain Metastasis: How to Define a Role for Temozolomide (2007) (6)
- On the significance of telomerase activity in human malignant glioma cells. (2000) (6)
- 2010: neuro-oncology is moving! (2010) (6)
- Glioblastoma multiforme: Mechanisms of resistance to chemotherapy (1999) (6)
- Intra-CSF liposomal cytarabine plus systemic therapy as initial treatment of breast cancer leptomeningeal metastasis: A randomised, open-label trial. (2018) (6)
- Role of TGF‐β in oncogenesis (2001) (5)
- 136 Complete Resection of Contrast-Enhancing Tumor Volume is Associated With Improved Survival in Recurrent Glioblastoma Results From the DIRECTOR Trial (2015) (5)
- The EGFRvIII transcriptome in glioblastoma: A meta-omics analysis (2021) (5)
- [Quantitative determination of 5 vitreal proteins in the normal vitreous body and proliferative retinal diseases]. (1990) (5)
- Serum iron levels in neuroleptic malignant syndrome (1993) (5)
- Effect of the integrin inhibitor cilengitide on TGF-beta signaling. (2012) (5)
- Management of Gliomas: Relevance of Molecular Markers for Clinical Practice (2011) (5)
- Underweight and weight loss are predictors of poor outcome in patients with brain metastasis (2019) (5)
- A 63‐YEAR‐OLD MAN WITH DEMENTIA, ATAXIA AND VI NERVE PALSY (2007) (5)
- Diagnostic value of 18 F-fluordesoxyglucose positron emission tomography for patients with brain metastasis from unknown primary site (2018) (5)
- Next generation neuro-oncology. (2018) (5)
- EH1.3 EORTC 26101 phase III trial exploring the combination of bevacizumab and lomustine versus lomustine in patients with first progression of a glioblastoma (2016) (5)
- Evaluation of distant spread in bevacizumab-treated versus control-treated patients with malignant gliomas: A matched-pair study. (2010) (5)
- Burnout and Career Satisfaction in Neuro-Oncology: A Survey of the Society for Neuro-Oncology and the European Association of Neuro-Oncology Membership. (2019) (5)
- P01.02 Biological role and therapeutic targeting of TGF-β3 in glioblastoma (2016) (5)
- Hemodynamic investigation of peritumoral impaired blood oxygenation-level dependent cerebrovascular reactivity in patients with diffuse glioma. (2020) (5)
- Expression and role of novel B7 family members in human muscle: implications for the pathogenesis of inflammatory myopathies (2004) (5)
- Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation: Final results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study. (2013) (5)
- A contemporary perspective on the diagnosis and treatment of diffuse gliomas in adults. (2020) (5)
- ACTR-11. SECOND INTERIM AND 1ST MOLECULAR ANALYSIS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CODELETION (2019) (5)
- How to define the opercular syndrome? (1992) (5)
- CD95/CD95 ligand-independent potentiation of treosulfan cytotoxicity by BSO in malignant glioma cells in vitro and in vivo. (2002) (5)
- [Vitronectin: mediator of cell adhesion in proliferative vitreoretinopathy?]. (1990) (5)
- Role of TGF-beta in oncogenesis. (2001) (5)
- [Analysis of the protein pattern in physiologic and pathologic vitreous bodies by electrophoresis and immunologic identification]. (1991) (5)
- Poly(ADP-ribose) polymerase-independent potentiation of nitrosourea cytotoxicity by 3-aminobenzamide in human malignant glioma cells. (2000) (5)
- Diagnostic value of WT 1 in neuroepithelial tumours (2009) (5)
- Very late relapses in glioblastoma long-term survivors. (2009) (5)
- Genetic Regulation and Therapeutic Modulation of Apoptosis in Human Malignant Glioma (1996) (5)
- Integrated phospho-proteogenomic and single-cell transcriptomic analysis of meningiomas establishes robust subtyping and reveals subtype-specific immune invasion (2021) (4)
- Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR—A Potential Therapeutic Target (2021) (4)
- Multifocal CNS demyelination after octreotide treatment for metastatic meningioma (2013) (4)
- Long-term survival in patients with primary CNS lymphoma: Results from the G-PCNSL-SG1 trial. (2015) (4)
- Cerebral angiography complications link cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy to familial hemiplegic migraine. (1996) (4)
- Intrathecal IgM response in disseminated cerebrospinal metastasis from malignant melanoma (1993) (4)
- Methylation of the p 73 gene in gliomas (4)
- Fibronectin quantification in plasma and vitreous by a noncompetitive ELISA technique (1988) (4)
- Assessing response to chemotherapy in malignant glioma: The role of steroids (1998) (4)
- Go, no-go decision making for phase 3 clinical trials: ACT IV revisited - Authors' reply. (2017) (4)
- BI-32RISK FACTOR ANALYSIS FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WHO DID NOT RECEIVE SALVAGE THERAPY (2014) (4)
- Adenoviral expression of XIAP antisense RNA induces apoptosis in glioma cells and suppresses the growth of xenografts in nude mice (2007) (4)
- Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet! (2016) (4)
- Nitropropionic acid-induced ischemia tolerance in the rat brain is mediated by reduced metabolic activity and cerebral blood (2017) (4)
- Anendogenous tumour-promoting ligand of the human aryl hydrocarbon receptor (2011) (4)
- Evidence-based management of adult patients with diffuse glioma - Authors' reply. (2017) (4)
- OS07.2 Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the ARTE trial (2017) (4)
- Identification of CD 70-mediated Apoptosis of Immune Effector Cells as a Novel Immune Escape Pathway of Human Glioblastoma 1 (2002) (4)
- Vaccination for IDH-mutant tumors: A novel therapeutic approach applied to glioma. (2021) (4)
- Should whole-brain radiotherapy be considered standard of care in newly diagnosed primary central nervous system lymphoma? The G-PCNSL-SG1 randomized phase IV trial. (2010) (4)
- PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression (2021) (4)
- Brain metastasis research: a late awakening. (2015) (4)
- Economic Impact of Poststroke Delirium and Associated Risk Factors (2021) (4)
- Are CSF or serum ganglioside antibodies related to peripheral nerve demyelination in neuroborreliosis, Guillain-Barré syndrome, or chronic inflammatory demyelinating polyradiculoneuropathy? (2005) (4)
- New insights into acquired temozolomide resistance in glioblastoma? (2015) (4)
- In search of cerebrospinal fluid biomarkers of fatigue in multiple sclerosis: A proteomics study (2018) (3)
- [Chemotherapy for brain tumors in adult patients]. (2008) (3)
- Determining the glioma CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide methylation data in the biomarker cohort of the NOA-04 trial. (2014) (3)
- Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O (2017) (3)
- Molecular genetic, host-derived and clinical determinants of long-term survival in glioblastoma: First results from the ETERNITY study (EORTC 1419). (2019) (3)
- CTNI-29. CODEL: PHASE III TRIAL OF RT ALONE, RT PLUS TMZ, OR TMZ ALONE FOR NEWLY-DIAGNOSED, 1p/19q CODELETED ANAPLASTIC OLIGODENDROGLIOMA. ANALYSIS FROM THE INITIAL STUDY DESIGN. (NCCTG N0577, ALLIANCE) (2020) (3)
- Immunoglobulin G, complement factor C3 and lymphocytes in proliferative intraocular disorders (1990) (3)
- Angiogenesis and Invasion (2010) (3)
- Phase I study of anti-PlGF monoclonal antibody (mAb) RO5323441 (RO) and anti-VEGF mab bevacizumab (BV) in patients with recurrent glioblastoma (GBM). (2013) (3)
- [Basic principles of diagnosis and treatment of gliomas]. (2018) (3)
- More on the immune privilege of glioblastoma. (2012) (3)
- Mononuclear Phagocytes in Proliferative Vitreoretinopathy (PVR). A Specific Role of Microglial Cells in Non-Traumatic Disease? (1991) (3)
- [In vitro changes in the lens epithelium and corneal endothelium caused by the cytostatic drug daunomycin]. (1989) (3)
- MGMT promoter methylation as a predictive biomarker for response to radiotherapy versus chemotherapy in malignant astrocytomas in the elderly: The NOA-08 trial. (2012) (3)
- TGF-beta2 suppression by the antisense oligonucleotide AP 12009 as therapy for high-grade glioma: safety and efficacy results of phase I/II clinical studies (2004) (3)
- Novel human monoclonal antibodies specific to the alternatively spliced domain D of Tenascin C efficiently target tumors in vivo (2020) (3)
- ACTR-39. TWO-YEAR RESULTS OF THE INTELLANCE 2/EORTC TRIAL 1410 RANDOMIZED PHASE II STUDY ON DEPATUX–M ALONE, DEPATUX-M COMBINED WITH TEMOZOLOMIDE (TMZ) AND EITHER TMZ OR LOMUSTINE IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA (NCT02343406 (2018) (3)
- Clozapine and neuroleptic malignant syndrome: a never-ending story. (1997) (3)
- Cells : A Potential Mechanism of Immune Paralysis Expression of the B 7-Related Molecule B 7-H 1 by Glioma Updated (2003) (3)
- [Mononuclear phagocytes and their growth factors: pacemakers of proliferative vitreoretinopathy?]. (1990) (3)
- Measuring change in health-related quality of life: the impact of different analytical methods on the interpretation of treatment effects in glioma patients (2020) (3)
- G-PCNSL-SG-1 randomized phase III trial of high-dose methotrexate with or without whole brain radiotherapy for primary central nervous system lymphoma: Long-term follow-up. (2014) (3)
- Autoimmune Myasthenia Gravis after Sternal Fracture (2012) (3)
- Evaluation of invasion patterns and their correlation with integrin alphavbeta expression in brain metastases of solid cancers. (2013) (3)
- Corrigendum to INTELLANCE 2/EORTC 1410 randomized phase II study of Depatux-M alone and with temozolomide vs temozolomide or lomustine in recurrent EGFR amplified glioblastoma (2020) (3)
- Muscle ® bres and cultured muscle cells express the B 7 . 1 / 2-related inducible co-stimulatory molecule , ICOSL : implications for the pathogenesis of in ̄ ammatory myopathies (2003) (3)
- A drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent local relapse and treat established brain metastasis (2020) (3)
- IMMUNOTHERAPY/BIOLOGICAL THERAPIES (2013) (3)
- Pathological yawning (chasm) associated with periodic leg movements in sleep: cure by levodopa (1999) (3)
- [Contractile elements in proliferative retinal diseases]. (1992) (3)
- Vitronectin and proliferative intraocular disorders. II. Expression of cell surface receptors for fibronectin and vitronectin in periretinal membranes (1991) (3)
- ATIM-47. NIVOLUMAB VS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA: EXPLORATORY ANALYSIS OF MGMT METHYLATION STATUS AND BASELINE CORTICOSTEROID USE (2019) (3)
- Primary CNS lymphoma and HLA class I and II alleles in a German cohort of immunocompetent patients (2008) (3)
- Novel cases of amyotrophic lateral sclerosis after treatment of cerebral arteriovenous malformationss. (2016) (3)
- Antidepressant drug use in glioblastoma patients: an epidemiological view. (2020) (3)
- 26LBA Does valproic acid improve survival in glioblastoma? A meta-analysis of randomized trials in newly diagnosed glioblastoma (2015) (3)
- “Nanomania” ante portas of neurooncology? (2011) (3)
- Elevated levels of fibronectin in the CSF: what do they signify? (1992) (3)
- Distinct Cerebrovascular Reactivity Patterns for Brain Radiation Necrosis (2021) (3)
- Clozapine-induced neuroleptic malignant syndrome: another inconclusive case report. (1996) (3)
- Vitronectin and proliferative intraocular disorders. II. Expression of cell surface receptors for fibronectin and vitronectin in periretinal membranes (1991) (3)
- ACTR-04. RESULTS OF THE INTERIM ANALYSIS OF THE EORTC RANDOMIZED PHASE III CATNON TRIAL ON CONCURRENT AND ADJUVANT TEMOZOLOMIDE IN ANAPLASTIC GLIOMA WITHOUT 1p/19q CO-DELETION, AN INTERGROUP TRIAL (2016) (3)
- DRES-14. OVERCOMING TEMOZOLOMIDE RESISTANCE IN EXPERIMENTAL GLIOMAS: MRI-GUIDED FOCUSED ULTRASOUND-MEDIATED BLOOD-BRAIN BARRIER OPENING FACILITATES THE LOCAL DELIVERY OF LIPOSOME ENCAPSULATED MGMT INHIBITORS (2017) (3)
- International Hermelin Brain Tumor Center Symposium on Apoptosis (2003) (3)
- From first symptoms to diagnosis: Initial clinical presentation of primary brain tumors (2020) (3)
- ET-12PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA (2014) (3)
- DNA methylation-based age acceleration observed in IDH wild-type glioblastoma is associated with better outcome—including in elderly patients (2022) (3)
- The HLA Ligand Atlas: A novel immuno-oncology resource for T-cell antigen discovery. (2020) (3)
- Meeting Update—World Federation of Neuro-Oncology Societies (WFNOS) Meeting 2017 (2017) (3)
- CD95 gene deletion may reduce clonogenic growth and invasiveness of human glioblastoma cells in a CD95 ligand-independent manner (2022) (2)
- Clinical and molecular subgroups of ependymoma in adulthood: An analysis of the German Glioma Network. (2017) (2)
- Association of perioperative adverse events with subsequent therapy and overall survival in patients with WHO grade III and IV gliomas (2021) (2)
- [Proliferative vitreoretinopathy. Activation of the complement system]. (1992) (2)
- Interferon-b Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells (2014) (2)
- [Severe dysphagia and erythrodermia in a 59-year-old man]. (2013) (2)
- Does extent of resection matter in recurrent glioblastoma? Lessons from the DIRECTOR trial. (2015) (2)
- [The antiphospholipid syndrome. The neurological complications and the therapeutic possibilities]. (2008) (2)
- Gene-Tailored Treatments for Brain Disorders: Challenges and Opportunities (2016) (2)
- [Clozapine: a neuroleptic at risk of provoking neuroleptic malignant syndrome (NMS) or an alternative neuroleptic with positive NMS case histories?]. (1993) (2)
- Apoptosis Pathways and Chemotherapy (2006) (2)
- [Electroconvulsive therapy in treatment of acute life threatening catatonia in toxic epidermal necrolysis (Lyell syndrome)]. (1992) (2)
- Impaired speed-dependent modulation of the gait pattern in multiple sclerosis (2020) (2)
- Negative allosteric modulators of metabotropic glutamate receptor 3 target the stem-like phenotype of glioblastoma (2020) (2)
- Design and Characterization of Novel Antibody-Cytokine Fusion Proteins Based on Interleukin-21 (2022) (2)
- P08.32 TG02, an oral CDK inhibitor, demonstrates activity in glioma models: EORTC Brain Tumor Group Conducts Phase 1b study (STEAM / EORTC 1608). (2016) (2)
- Prime time for molecular marker diagnostics in neuro-oncology. (2012) (2)
- Radiochemotherapy with daily concomitant and adjuvant one week on/one week off temozolomide plus indomethacin in newly diagnosed glioblastoma: A phase II trial (2008) (2)
- Tumor necrosis factor-directed therapy of autoimmune encephalomyelitis by the phosphodiesterase IV inhibitor rolipram (1994) (2)
- Molecular MR-Imaging for Noninvasive Quantification of the Anti-Inflammatory Effect of Targeting Interleukin-1β in a Mouse Model of Aortic Aneurysm (2020) (2)
- Atnt-10Does Valproic Acid Improve Survival In Glioblastoma? A Meta-Analysis Of Randomized Trials In Newly Diagnosed Glioblastoma (2015) (2)
- A tumor-promoting role for soluble TβRIII in glioblastoma (2021) (2)
- MGMT promoter methylation status and DNA mismatch repair genes in paired primary and recurrent glioblastoma: A translational study of the German Glioma Network. (2010) (2)
- Overall patient’s survival of glioblastoma associated to molecular markers: a pan-proteomic prospective study (2020) (2)
- Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: Efficacy and imaging analyses of the ARTE trial. (2017) (2)
- Letter to the Editor. Phase III randomized controlled trials are essential to properly evaluate the role of radiotherapy in WHO grade II meningioma. (2018) (2)
- Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. (2021) (2)
- ATIM-16. PHASE 1 STUDY RESULTS OF M7824 (MSB0011359C), A BIFUNCTIONAL FUSION PROTEIN TARGETING TGF- AND PD-L1, AMONG PATIENTS WITH RECURRENT GLIOBLASTOMA (rGBM) (2018) (2)
- EXPERIMENTAL THERAPEUTICS AND PHARMACOLOGY (2013) (2)
- Reply: Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels. (2016) (2)
- Treatment failure due to intracerebral stem cell-like behavior of glioblastoma (GBM) cells: A reason for targeted maintenance therapy with imatinib (I) and hydroxyurea (H)? An analysis of study DE21 and DE40 (Ambrosia) (2008) (2)
- [Ross syndrome: Adie syndrome with disorders of sweat and body temperature regulation]. (1991) (2)
- [Standards and new developments in the chemotherapy of glioblastomas]. (2005) (2)
- Oxford Textbook of Neuro-Oncology (2017) (2)
- One week on/one week off regimen of temozolomide for recurrent glioblastoma: A phase II study. (2004) (2)
- [Anti-phospholipid antibodies and cerebral ischemia]. (1992) (2)
- Abstract LB-80: ATRX loss refines the classification of anaplastic glioma and is a favorable prognostic marker. (2013) (2)
- HOW TO DEFINE THE OPERCULAR SYNDROME ? REPLY (1992) (2)
- Is the serum glucose/potassium ratio a reliable prognostic factor for aneurysmal SAH? TO THE EDITOR (2018) (2)
- m6A Regulator Expression Segregates Meningiomas Into Biologically Distinct Subtypes (2021) (2)
- Tumour necrosis factor-alpha in malignant melanomatous meningitis. (1992) (2)
- CELL BIOLOGY AND SIGNALING (2010) (2)
- Surgery for patients with 'lower grade' glioma: putting assumptions, beliefs and convictions into perspective. (2017) (2)
- ACTR-30. EORTC 1608: A PHASE 1B STUDY OF TG02, AN ORAL CYCLIN-DEPENDENT KINASE 9/5 INHIBITOR, IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA STRATIFIED BY MGMT PROMOTER METHYLATION STATUS (2016) (2)
- Hemodynamic Imaging in Cerebral Diffuse Glioma—Part A: Concept, Differential Diagnosis and Tumor Grading (2022) (2)
- CELL BIOLOGY AND SIGNALING (2010) (2)
- CMET-39. INTRA-CSF LIPOSOMAL CYTARABINE PLUS SYSTEMIC THERAPY AS INITIAL TREATMENT OF BREAST CANCER LEPTOMENINGEAL METASTASIS: A RANDOMISED, OPEN-LABEL TRIAL (2018) (2)
- Microglia: a novel treatment target in gliomas. (2012) (2)
- An endogenous ligand of the human aryl hydrocarbon receptor promotes tumor formation (2017) (2)
- PROGNOSTIC AND PREDICTIVE BIOMARKER-BASED SUBGROUPS IN THE NOA-04 TRIAL (2014) (2)
- Estimated clinical efficacy and radiographic response characteristics of PD1 inhibition in newly diagnosed and recurrent glioblastoma in clinical practice: A report from the iRANO Working Group. (2020) (2)
- Clinical Epidermal Growth Factor Receptor Variant III ( EGFRvIII ) Positivity in EGFR-Ampli fi ed Glioblastomas : Prognostic Role and Comparison between Primary and Recurrent Tumors (2017) (2)
- Diagnosis and Treatment of Pineal Region Tumors in Adults: A EURACAN Overview (2022) (2)
- [Lactoferrin and transferrin--iron-binding proteins in physiological and pathological vitreous bodies]. (1990) (1)
- Current State of Immune-Based Therapies for Glioblastoma. (2016) (1)
- CTNI-38. PAMIPARIB IN COMBINATION WITH RADIATION THERAPY (RT) AND/OR TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED (ND) OR RECURRENT/REFRACTORY (R/R) GLIOBLASTOMA (GBM); PHASE 1B/2 STUDY UPDATE (2020) (1)
- [Traction detachment in Coats disease]. (1988) (1)
- Autocrine VEGFR 1 and VEGFR 2 signaling promotes survival in human glioblastoma models in vitro and in vivo (2016) (1)
- Chapter 65 – Leptomeningeal Metastasis (2003) (1)
- The epigenetic evolution of gliomas is determined by their IDH1 mutation status and treatment regimen (2021) (1)
- AT-59HIGH-DOSE MTX-BASED CHEMOTHERAPY FOR PRIMARY CNS LYMPHOMA: WITH OR WITHOUT WHOLE BRAIN RADIOTHERAPY? FINAL ANALYSIS OF G-PCNSL-SG-1 (2014) (1)
- Diagnostic and Therapeutic Strategies for Recurrent Gliomas (2007) (1)
- IMMU-54. CD317 EXPRESSION IN HUMAN GLIOBLASTOMA: A TARGET FOR IMMUNOTHERAPY (2017) (1)
- Improving outcome in newly diagnosed malignant glioma (2017) (1)
- Evolution of glioblastoma (2009) (1)
- [Anaplastic glioma. Neuropathology, molecular diagnostics and current study concepts]. (2010) (1)
- Prospective evaluation of meningeal involvement in primary CNS lymphoma (PCNSL) (2008) (1)
- Prion diseases: Movement disorders reveal Creutzfeldt–Jakob disease (2009) (1)
- Abstract 4: Antitumor activity of DLX1008, a single chain antibody fragment binding to VEGF-A, in in vivo preclinical models of Kaposi sarcoma and glioblastoma (2018) (1)
- World Federation of Neuro-Oncology Societies (2019) (1)
- Single cell mapping of human brain tumors reveals tumor-specific education of tissue-invading leukocytes. (2020) (1)
- Radiotherapy for glioblastoma patients with poor performance status (2021) (1)
- FAST TRACK Modulation of TGF-b activity by latent TGF-b-binding protein 1 in human malignant glioma cells (2009) (1)
- 40. AN UPDATE ON THE DEVELOPMENT OF A NEW TOOL TO ASSESS RESPONSE IN LEPTOMENINGEAL METASTASIS (2020) (1)
- Embolization of tumor cells is rare in patients with systemic cancer and cerebral large vessel occlusion (2020) (1)
- Reply to glioblastoma in the Canton of Zurich, Switzerland revisited: 2005 to 2009 (2016) (1)
- Primary Central Nervous System Lymphoma in the Elderly (2014) (1)
- The molecular evolution of glioblastoma treated by gross total resection alone. (2020) (1)
- Corrigendum: Computer-assisted quantification of motile and invasive capabilities of cancer cells (2018) (1)
- Comparison of high-dose methotrexate (HDMTX) toxicity in elderly and younger patients (pts) with primary central nervous system lymphoma (PCNSL). (2004) (1)
- LTBK-12. EORTC 26951, RANDOMIZED STUDY OF ADJUVANT PCV AFTER 59.4 GY RADIOTHERAPY: VERY LONG TERM FOLLOW-UP (2019) (1)
- CTNI-23. IDH1/2wt ANAPLASTIC GLIOMAS OF THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON TRIAL: OVERALL SURVIVAL RELATED TO TREATMENT, MGMT STATUS AND MOLECULAR FEATURES OF GLIOBLASTOMA (2020) (1)
- Proteases Cytoplasmic and Secreted Furin-Like 1 , 2 by Human Glioblastoma Cells Involves β Processing of Immunosuppressive Pro-TGF (2001) (1)
- Peptide-Specific Vaccines (2017) (1)
- Abstract 1504: Tumor-treating fields (TTFields) interfere with biological key properties of glioma cells in vitro (2017) (1)
- Long-term survival in primary glioblastoma revisited: The contribution of isocitrate dehydrogenase mutations. (2013) (1)
- [Isoelectric focusing and electroblotting of human vitreous body proteins]. (1989) (1)
- Systemic Relapses In Primary CNS Lymphoma (PCNSL) - Unexpected Clonal Diversity (2010) (1)
- Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling (2020) (1)
- Impact of meningeal dissemination (MD) on outcome in primary CNS lymphoma in the G-PCNSL-SG1 trial. (2011) (1)
- Correlation of IDH mutation, 1p/19q co-deletion and 18FET-PET derived time-to-peak analysis as prognostic markers in glioma (2016) (1)
- Molecular Genetic, Host-Derived and Clinical Determinants of Long-Term Survival in Glioblastoma: First Results from the Brain Tumor Funders' Collaborative Consortium (2016) (1)
- P02.04MICRORNA-MEDIATED DOWN-REGULATION OF NKG2D LIGAND EXPRESSION REDUCES GLIOMA CELL IMMUNOGENICITY. (2014) (1)
- Bevacizumab plus radiotherapy for elderly patients with glioblastoma (ARTE). (2012) (1)
- Elderly patients with primary CNS lymphoma: Results from the G-PCNSL-SG-1 trial. (2012) (1)
- PATH-11. PROGNOSTIC SIGNIFICANCE OF EPIGENETIC SUBTYPES AND CpGs ASSOCIATED WITH PROGRESSION TO G-CIMP LOW IN THE EORTC RANDOMIZED PHASE III INTERGROUP CATNON (2020) (1)
- [Challenges and future perspectives in neuro-oncology]. (2019) (1)
- Ganglioside Antibodies Major Depression in Schizophrenia and (1992) (1)
- HG-68COMBINED ALTERATIONS IN MAPK PATHWAY GENES, CDKN2A/B AND ATRX CHARACTERIZE ANAPLASTIC PILOCYTIC ASTROCYTOMA (2016) (1)
- [Immunohistology of proliferative vitreoretinopathy following giant tear detachment]. (1989) (1)
- NCOG-02. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS (2020) (1)
- Therapy Resistance of Glioblastoma Stem Cells Induces Loss of Spherogenicity and Overcomes (2014) (1)
- RARE-19. CHEMOTHERAPY FOR SPINAL GLIOMAS IN ADULTS: A RETROSPECTIVE STUDY (2018) (1)
- Hemodynamic Imaging in Cerebral Diffuse Glioma—Part B: Molecular Correlates, Treatment Effect Monitoring, Prognosis, and Future Directions (2022) (1)
- COMMONLY INACTIVATED BY DNA MUTATIONS AND DELETIONS IN EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (EMZL) (2008) (1)
- Cancer is associated with inferior outcome in patients with ischemic stroke (2021) (1)
- 41. PROGNOSTIC VALIDATION OF THE EANO ESMO CLASSIFICATION OF LEPTOMENINGEAL METASTASIS (2020) (1)
- NIMG-75. NECROSIS DURING TREATMENT IS ASSOCIATED WITH WORSE SURVIVAL IN RECURRENT GLIOBLASTOMA PATIENTS – POST HOC IMAGE ANALYSIS OF EORTC 26101 (2017) (1)
- Clinical and molecular features associated with long-term survival of elderly patients with glioblastoma. (2017) (1)
- ACTR-05. THE RANDOMIZED PHASE II ARTE TRIAL: BEVACIZUMAB PLUS HYPOFRACTIONATED RADIOTHERAPY VERSUS RADIOTHERAPY ALONE IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2017) (1)
- Molecular classification of diffuse cerebral gliomas using genome- and transcriptome-wide profiling. (2015) (1)
- Role of Integrins in Angiogenesis (2013) (1)
- Erratum to: Gliomatosis cerebri: no evidence for a separate brain tumor entity (2016) (1)
- 32. TREATMENT MONITORING OF IMMUNOTHERAPY AND TARGETED THERAPY USING AMINO ACID PET IN PATIENTS WITH BRAIN METASTASES (2020) (1)
- MNGO-20SOMATOSTATIN RECEPTOR-TARGETED RADIONUCLIDE THERAPY FOR PROGRESSIVE MENINGIOMA. (2015) (1)
- Unusual presentation of central nervous system metastases: mechanisms of spread and radiological findings. (2008) (1)
- OMICS AND PROGNSTIC MARKERS (2013) (1)
- Prognostic value of 18FET positron emission tomography (18FET-PET) for the clinical course in newly diagnosed glioblastoma. (2013) (1)
- Association of aggressive resection with survival and progression-free survival in adult low-grade glioma: A systematic review and meta-analysis with numbers needed to treat. (2017) (1)
- Pathway-based stratification of glioblastoma (2021) (1)
- Whole-brain radiotherapy in primary CNS lymphoma – Authors' reply (2011) (1)
- Toxic light levels induce programmed cell death (apoptosis) in the rat retina (1994) (1)
- [New developments in diagnosis and therapy of primary non-Hodgkin's lymphoma of the central nervous system]. (1997) (1)
- Reply to F. Felix et al and M.F. Fay et al. (2016) (1)
- Cancer Biology and Signal Transduction Interferon-b Induces Loss of Spherogenicity and Overcomes Therapy Resistance of Glioblastoma Stem Cells (2014) (1)
- ACTR-53. STEAM / EORTC 1608: STUDY OF TG02 IN ELDERLY NEWLY DIAGNOSED OR ADULT RELAPSED PATIENTS WITH ANAPLASTIC ASTROCYTOMA OR GLIOBLASTOMA - A PHASE 1B STUDY (2018) (1)
- [Vitronectin and fibronectin receptors in proliferative retinal diseases]. (1990) (1)
- QLIF-47. HEALTH RELATED QUALITY OF LIFE AND NEUROLOGICAL DETERIORATION FREE SURVIVAL IN INTELLANCE 2/EORTC TRIAL 1410, A RANDOMIZED PHASE II STUDY ON ABT414 IN RECURRENT EGFR AMPLIFIED GLIOBLASTOMA (2017) (1)
- Interferon-β exposure induces a fragile glioblastoma stem cell phenotype with a transcriptional profile of reduced migratory and MAPK pathway activity (2020) (1)
- Gender issues from the perspective of health-care professionals in Neuro-oncology: an EANO and EORTC Brain Tumor Group survey. (2020) (1)
- Elderly people with glioblastoma - Authors' reply (2012) (1)
- Brain Metastases from Systemic Solid Tumors (2003) (1)
- Fitness-to-drive for glioblastoma patients: Guidance from the Swiss Neuro-Oncology Society (SwissNOS) and the Swiss Society for Legal Medicine (SGRM). (2021) (1)
- PO24-TH-13 Vigilance impairment and its association with severity of motor symptoms, depression, cognition, and dopaminergic treatment in idiopathic Parkinson disease (2009) (0)
- Glioblastoma in the era of bevacizumab: An epidemiological study in the Canton of Zurich, Switzerland, 2010-2014. (2018) (0)
- EXTH-35. THERAPEUTIC TARGETING OF TGF-β1/2 IN GLIOBLASTOMA USING NOVEL ANTISENSE OLIGONUCLEOTIDES (2016) (0)
- P08.62 Extracellular signal-regulated kinase 1 (ERK1) mediates the autocrine positive feedback loop of TGF-β and furin in glioblastoma stem cells (2017) (0)
- Immune escape of malignant gliomas – regulation of NKG2D ligands by TGF-beta and matrix metalloproteinases (2005) (0)
- 13.4 Tumorinfiltration des Nervensystems per continuitatem (2003) (0)
- Erratum to: Prognostic validation and clinical implications of the EANO ESMO classification of leptomeningeal metastasis from solid tumors. (2021) (0)
- Avastin and Malignant Gliomas (2010) (0)
- Objective responses to chemotherapy in recurrent glioma: A prospective analysis from the German Glioma Network. (2011) (0)
- Brain Tumor Imaging (2015) (0)
- [First description of Ross syndrome by Hans Hüetlin]. (1998) (0)
- 7.1 Gliome (2003) (0)
- Genetic variants of folate and methionine metabolism and primary central nervous system lymphoma incidence in a German cohort of 185 patients (2009) (0)
- The DEPOSEIN - how meaningful was the benefit from intrathecal chemotherapy? (2020) (0)
- 11.6 Zerebrale Manifestationen (2003) (0)
- 14.1 Chemotherapie (2003) (0)
- Use of blockers of the NKG2D receptor / NKG2D ligand interaction in autoimmune diseases (2004) (0)
- A novel hexameric CD95 ligand as a potent agonist of apoptosis in human glioma cells in vitro and in vivo (2007) (0)
- ACTR-16. PERIPHERAL BLOOD CD4+ MONONUCLEAR CELL FRACTIONS ARE ASSOCIATED WITH OVERALL SURVIVAL AT FIRST RECURRENCE OF IDH-WILDTYPE GLIOBLASTOMA AFTER STANDARD CHEMORADIOTHERAPY: SECONDARY ANALYSES OF THE PHASE II DIRECTOR TRIAL (2018) (0)
- Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup. (2019) (0)
- [Intrathecal immune response in meningeosis neoplastica: IgG, IgM, oligoclonal bands and cytokines]. (1992) (0)
- 116 INVITED Targeted therapies and anti-angiogenic treatments in newly diagnosed malignant glioma (2007) (0)
- Inhibition of glioma cell growth in vitro and in vivo by a novel proteasome inhibitor (2009) (0)
- EANM / EANO / RANO practice guidelines / SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [ F-18 ] FDG (2019) (0)
- Dedication: Andrew T. Parsa. (2015) (0)
- Subpial haemorrhage: clinical presentation, neuroradiological findings and therapeutic consequences (2007) (0)
- Author and Subject Index (2002) (0)
- PATH-24. MOLECULAR SUBGROUPS OF ADULT EPENDYMAL TUMORS: AN ANALYSIS OF THE GERMAN GLIOMA NETWORK (2017) (0)
- Mutational Status in Genes of Folate Metabolism Is Associated with Toxicity of High-Dose Methotrexate in Patients with Immunocompetent Primary Central Nervous System Lymphoma. (2006) (0)
- CNS Tumors in Older Adults (2020) (0)
- NEUROCOGNITIVE OUTCOMES OF EORTC BRAIN TUMOR GROUP STUDY 26101 PHASE III TRIAL COMPARING THE COMBINATION OF LOMUSTINE AND BEVACIZUMAB WITH LOMUSTINE ALONE IN GLIOBLASTOMA PATIENTS WITH FIRST PROGRESSION (2017) (0)
- MNGI-14. LOSS OF HISTONE H3K27me3 IDENTIFIES A SUBSET OF MENINGIOMAS WITH INCREASED RISK OF RECURRENCE (2018) (0)
- Current Treatment Strategies for Malignant Gliomas (2007) (0)
- Contents Vol. 61(2003) (2004) (0)
- EPID-10. VENOUS THROMBOEMBOLIC EVENTS IN GLIOBLASTOMA PATIENTS: AN EPIDEMIOLOGICAL VIEW (2019) (0)
- 9204 Toxicity of high-dose methotrexate (HDMTX) based chemotherapy in primary CNS lymphoma (PCNSL): preliminary experience from a randomized phase III study (G-PCNSL-SG1, NCT00153530) (2009) (0)
- Explorer Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells (2017) (0)
- PATH-51. DNA COPY NUMBER PROFILING ACROSS GLIOBLASTOMA POPULATIONS HAS IMPLICATIONS FOR CLINICAL TRIAL DESIGN (2018) (0)
- Hotspots in Neuro-Oncology Cognitive Functions in Primary CNS Lymphoma after Single or Combined Modality Regimens on the Role of Human Cytomegalovirus in Glioblastoma (2017) (0)
- Reply (1998) (0)
- [Changes in survival by combined radio-chemotherapy]. (2004) (0)
- Challenges in the diagnoses and treatment of CNS tumors. (2019) (0)
- 5.2 Operative Therapie (2003) (0)
- Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities (2019) (0)
- Anaplastic pilocytic astrocytoma-an IDH-wildtype diffuse glioma characterized by a distinct DNA methylation profile and combined alterations in MAPK pathway genes, CDKN2A/B and ATRX (2017) (0)
- Diagnostics and Diagnosis of Late Effects in Childhood Brain Tumour Survivors (2020) (0)
- Exploiting Apoptosis Pathways for Glioblastoma Therapy (2008) (0)
- Erratum to: Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05) (2011) (0)
- 24. LOCAL TUMOR PROGRESSION IS A RISK FACTOR FOR POSTOPERATIVE SEIZURES IN PATIENTS WITH BRAIN METASTASIS (2020) (0)
- Polymorphisms in genes of folate metabolism and effects of high-dose methotrexate in patients with primary central nervous system lymphoma. (2006) (0)
- 372MO Melanoma leptomeningeal metastases: A European multicenter cohort (2020) (0)
- Vulnerability of invasive glioma cells to lysosomal membrane instabilization (2018) (0)
- [Detection of coagulation factor XIII in the vitreous body and periretinal membranes in proliferative retinal diseases]. (1990) (0)
- Abstract LB-055: Novel therapeutic option targeting the tumor cell lysosomes (2020) (0)
- Bevacizumab (Avastin®) and Malignant Glioma: Is there a Role? A European Perspective (2010) (0)
- Antibodies against gangliosides in myasthenia gravis (MG) (1991) (0)
- PS1 - 177 Diagnosing and Treating Leptomeningeal Metastasis across Europe: A Web-Based Survey (2016) (0)
- Management of Paranoid Psychosis in the Lactation Period with Clozapine (1992) (0)
- ACTR-64. OBJECTIVE RESPONSES TO CHEMOTHERAPY IN RECURRENT GLIOMA DO NOT PREDICT BETTER SURVIVAL: A PROSPECTIVE ANALYSIS FROM THE GERMAN GLIOMA NETWORK (2018) (0)
- Important themes in Neuro-Oncology Practice: Rare brain tumors, radiotherapy and its side effects, and supportive and palliative care. (2020) (0)
- P08.47 Crosstalk of the HGF/c-MET and TGF-β pathways in glioblastoma (2017) (0)
- ANGI-12EFFICACY OF THE PENTRA®BODY DLX1008, A MONOVALENT ANTIBODY FRAGMENT WITH LOW PICOMOLAR AFFINITY TO VEGF-A, IN HUMAN GLIOMA MODELS IN VITRO AND IN VIVO (2015) (0)
- In vivo and In vitro Cells Enhances Immunogenicity of Murine and Human Glioma Kinase Inhibitor , Inhibits Growth and Invasiveness and Receptor I β SD-208 , a Novel Transforming Growth Factor (2004) (0)
- Reply (2011) (0)
- [Chemotherapy of brain tumors in aduts]. (2015) (0)
- CMET-26. PERIOPERATIVE IMAGING OF BRAIN METASTASES: A EUROPEAN ASSOCIATION OF NEURO-ONCOLOGY (EANO) YOUNGSTERS SURVEY (2018) (0)
- BIOM-59. TERT PROMOTER MUTATION AND MGMT PROMOTER METHYLATION-MEDIATED SENSITIVITY TO TEMOZOLOMIDE IN IDH-WILDTYPE GLIOBLASTOMA: IS THERE A LINK? (2020) (0)
- ACTR-61. LONG-TERM ANALYSES OF THE NOA-08 RANDOMIZED PHASE III TRIAL (2018) (0)
- Malignant Hyperthermia and Neuroleptic Malignant Syndrome (2003) (0)
- IMMU-08. THE ANTIGENIC LANDSCAPE OF GLIOBLASTOMA - REFINING THE TARGETS FOR IMMUNOTHERAPY (2019) (0)
- Brief Communications PCV chemotherapy for recurrent glioblastoma (2011) (0)
- MicroRNAs in Primary Brain Tumors: Functional Impact and Potential Use for Diagnostic Purposes (2014) (0)
- Angiogenesis inhibition: quo vadis? (2012) (0)
- Induction of atypical anoikis in glioma cells through inhibition of integrin functions. (2013) (0)
- - 1-HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells (0)
- P02.07INTERFERON-β MODULATES THE INNATE IMMUNE RESPONSE AGAINST GLIOBLASTOMA INITIATING CELLS. (2014) (0)
- Sensitization of glioblastoma to alkylating chemotherapy by ultrasound-mediated delivery of therapeutic liposomes. (2018) (0)
- CS-12TRANSFORMING GROWTH FACTOR-β PATHWAY ACTIVITY IN GLIOBLASTOMA (2014) (0)
- Clinical trials in neuro-oncology: one step forward, two steps back? (2011) (0)
- P08.22 The NKG2D System mediates anti-tumor effects of chemotherapy and radiotherapy against glioblastoma (2016) (0)
- EPID-16PATTERNS OF CARE AND OUTCOME IN GLIOBLASTOMA PATIENTS IN THE CANTON OF ZURICH: A POPULATION-BASED STUDY (2005-2009) (2015) (0)
- Integrin for use in the treatment of cancer (2008) (0)
- Development and Validation of an Individualized Predictor of Meningioma Recurrence: A Multicenter Retrospective Cohort Study (2019) (0)
- 1.054 SLEEP, SLEEPINESS AND VIGILANCE IN DOPAMINE- AND HYPOCRETIN DEFICIENT DISORDERS (2012) (0)
- NIMG-34. 18FET-PET UPTAKE DYNAMICS SERVES AS AN ADDITIONAL IMAGING BIOMARKER IN ASTROCYTOMAS WITH IDH1/2 MUTATION AND NO LOH1p/19q (2016) (0)
- PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED (2021) (0)
- C.07 Predicting individualized risk of recurrence: development and validation of a DNA-methylation based nomogram in meningioma (2019) (0)
- Intravenous vs. intra-arterial methotrexate-based chemotherapy regimens for newly diagnosed primary central nervous system lymphoma. (2016) (0)
- Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate (2018) (0)
- IMMU-53. IMPACT OF TUMOR-TREATING FIELDS (TTFIELDS) ON THE IMMUNOGENICITY OF GLIOMA CELLS (2018) (0)
- Anti-ganglioside antibodies in myasthenia gravis (MG) (1991) (0)
- Cancer Therapy : Preclinical SC 68896 , a Novel Small Molecule Proteasome Inhibitor , Exerts Antiglioma Activity In vitro and In vivo (2009) (0)
- CS-35TGF-β INDUCES AND BMP SUPPRESSES VEGF RELEASE DEPENDING ON SMAD2/3 VERSUS SMAD1/5/8 SIGNALING IN GLIOBLASTOMA (2014) (0)
- Venous thromboembolic events in glioblastoma patients: Common complication but not a major reason for death. (2020) (0)
- CD95 gene deletion may reduce clonogenic growth and invasiveness of human glioblastoma cells in a CD95 ligand-independent manner (2022) (0)
- Preclinical Therapy SC 68896 , a Novel Small Molecule Proteasome Inhibitor , Exerts Antiglioma Activity In vitro and In vivo (2009) (0)
- Polymorphisms in Genes of Folate Metabolism and Response to High-Dose Methotrexate in Patients with Primary Central Nervous System Lymphoma. (2005) (0)
- P01.034 Prospective evaluation of alternative therapies in glioma patients in France (2018) (0)
- MOLECULAR GENETIC DETERMINANTS OF LONG-TERM SURVIVAL WITH GLIOBLASTOMA (2014) (0)
- CSIG-06. DEPATUXIZUMAB MAFODOTIN (ABT-414)-INDUCED GLIOBLASTOMA CELL DEATH REQUIRES EGFR OVEREXPRESSION, BUT NOT PHOSPHORYLATION (2019) (0)
- Appropriate Analysis of Duration of Response Data in Cancer Trials-Reply. (2020) (0)
- MNGI-05. DEVELOPMENT AND VALIDATION OF A DNA METHYLOME-BASED PREDICTOR OF MENINGIOMA RECURRENCE AND MENINGIOMA RECURRENCE SCORE (2018) (0)
- EXTH-21. MECHANISMS OF SYNERGISTIC GROWTH SUPPRESSION BY RADIOTHERAPY AND C-MET INHIBITION IN EXPERIMENTAL GLIOBLASTOMA (2021) (0)
- INHIBITING INVASION AND STEMNESS IN GLIOBLASTOMA BY THYMOSIN BETA 4 GENE SILENCING: A POTENTIAL THERAPEUTIC TARGET? (2014) (0)
- Shaping the glioma immune microenvironment through tryptophan (2012) (0)
- Which Phencyclidine-Like N-Methyl-D-Aspartate Receptor Antagonists Are Currently Available for Clinical Use? (1998) (0)
- [Electroconvulsive therapy--sources of error and aids in insufficient duration of convulsions]. (1992) (0)
- Abstract 4736: N-myc downstream regulated gene 1: A novel mediator of hypoxia-driven chemoresistance in glioblastoma (2012) (0)
- Transforming growth factor-β pathway activity in human malignant gliomas - an in vivo study (S43.002) (2015) (0)
- P13.17 CD95 gene silencing affects growth and invasiveness of glioma-initiating cells in a CD95L-independent manner (2021) (0)
- MNGI-02. PREOPERATIVE EMBOLIZATION OF MENINGIOMA: INFERIOR NEUROLOGICAL OUTCOME, INCREASED RISK OF CARDIOVASCULAR COMPLICATIONS AND SHORTER TIME TO RECURRENCE? (2017) (0)
- Identification of single nucleotide polymorphism of PI3k-AKT-TOR pathway as a risk factor of central nervous system metastasis in metastatic breast cancer. (2017) (0)
- RARE-10. MULTICENTER PILOT STUDY OF RADIO-CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR ADULTS WITH MEDULLOBLASTOMA – THE NOA-07 TRIAL. (2017) (0)
- [Significance of fibronectins in proliferative retinal diseases]. (1988) (0)
- 5.5 Chemotherapie (2003) (0)
- Basics of Brain Tumor Biology for Clinicians (2019) (0)
- MPTH-23. LONG-TERM SURVIVAL WITH GLIOBLASTOMA IN THE ELDERLY (2016) (0)
- Immunotherapy for brain tumors checkpoint inhibitors, vaccines and beyond (2017) (0)
- Preclinical and clinical applications of enzastaurin in the treatment of malignant gliomas (2007) (0)
- Molecular neuro-oncology: new avenues in diagnosis and treatment (2012) (0)
- 14.2 Antiangiogenese (2003) (0)
- MLTI-09. UNDERWEIGHT AND WEIGHT LOSS ARE PREDICTORS OF POOR OUTCOME IN PATIENTS WITH BRAIN METASTASIS (2019) (0)
- Mutant BRAF confers transforming growth factor b addiction (2016) (0)
- CMET-26. DIAGNOSTIC VALUE OF FDG-PET/CT FOR PATIENTS WITH BRAIN METASTASIS FROM UNKNOWN PRIMARY SITE (2017) (0)
- Hydrocephalus Related to CNS Malignancies in Adults (2019) (0)
- 654 Gene expression profiling of human glioblastoma. A translational research study to the randomized trial EORTC 26981/NCIC CE.3 testing radiotherapy ± temozolomide (2004) (0)
- DIRECT CELL CONTACT BETWEEN BRAIN ENDOTHELIAL CELLS AND GLIOMA STEM CELLS PROMOTES ENDOTHELIAL CELL MIGRATION (2014) (0)
- Abstract B88: TGF-β pathway-mediated escape from VEGF blockade is linked with angiogenesis and immune-suppression in murine glioma models (2017) (0)
- Thymoma-associated limbic encephalitis: remission after thymectomy and rituximab (2009) (0)
- Chromosome 7 gain and DNA hypermethylation at the HOXA10 locus are associated with expression of a stem cell related HOX-signature in glioblastoma (2015) (0)
- Glioma tropism of haematopoietic progenitor cells is mediated by CXCL12 (2005) (0)
- BSCI-02. METPlatform identifies brain metastasis vulnerabilities and predicts patient response to therapy (2021) (0)
- NIMG-54. DIFFUSE TUMOR GROWTH PATTERN IS ASSOCIATED WITH WORSE OUTCOME ONLY IN IDH WILDTYPE BUT NOT IN IDH MUTANT GLIOMAS WHO II AND III (2020) (0)
- IS COGNITION ALTERED IN THE EKER RAT MODEL OF TUBEROUS SCLEROSIS COMPLEX (2006) (0)
- Role of surgery for glioblastoma: response to letters from Dr. Gerritsen and his colleagues and Dr. Vargas Lopez. (2021) (0)
- Contents Vol. 7, 2010 (2010) (0)
- Treatment of Leptomeningeal Metastases (2019) (0)
- Determinants of long-term survival in glioblastoma — EORTC 1419 (2017) (0)
- CTNI-20. PCV CHEMOTHERAPY ALONE IS ASSOCIATED WITH BETTER CLINICAL COURSE IN OLIGODENDROGLIOMA WHO GRADE II (2020) (0)
- P04.27 Texture feature analysis to predict overall survival in recurrent glioblastoma treated in the DIRECTOR trial (2017) (0)
- Control of VEGF release via TGF-β superfamily members in glioblastoma (P4.246) (2015) (0)
- Clinical, Imaging, and CSF Cytological Presentation of Leptomeningeal Metastases from Solid Non-CNS Primary Tumors (2019) (0)
- Modulating TGF-β Receptor Signaling: A Novel Approach of Cancer Therapy (2008) (0)
- Chemotherapy for adult patients with spinal cord gliomas. (2021) (0)
- Acknowledgement to Reviewers (2007) (0)
- P10.03 Management of low-grade glioma: a systematic review and meta-analysis. (2017) (0)
- Response to Supp/May (2005) (0)
- ACTR-47. PATIENTS WITH EGFR AMPLIFICATION BUT WITHOUT EGFRvIII EXPRESSION HAVE IMPROVED BENEFIT COMPARED TO THOSE WITH EGFRvIII EXPRESSION IN SAMPLES OF THE INTELLANCE 2/EORTC 1410 RANDOMIZED PHASE II TRIAL (2018) (0)
- Advances in Brief Inhibition of Epidermal Growth Factor Receptor Signaling Protects Human Malignant Glioma Cells from Hypoxia-Induced Cell Death (2004) (0)
- The value of 18F-fluordesoxyglucose positron emission tomography (FDG-PET/CT) in the detection of the primary lesion and for staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS). (2017) (0)
- IMMU-13. COMBINED MODULATION OF THE TGF-Β PATHWAY AND GITR IMMUNE CHECKPOINT SIGNALING PROMOTES ANTI-TUMOR IMMUNITY IN SYNGENEIC GLIOMA MODELS (2021) (0)
- Chromatin remodeler proteins exert an important function in promoting dynamic modifications in the chromatin architecture, performing a central role in regulating gene transcription. Deregulation of these molecular machines (2019) (0)
- NEUROCOGNITIVE FUNCTIONING IN EORTC BRAIN TUMOR GROUP RANDOMIZED PHASE II TAVAREC TRIAL (EORTC 26091, NCT01164189) ON TEMOZOLOMIDE WITH OR WITHOUT BEVACIZUMAB in 1p/19q INTACT RECURRENT GRADE II AND III GLIOMAS (2017) (0)
- MLTI-13. RESPONSE ASSESSMENT OF MELANOMA BRAIN METASTASES TREATED BY STEREOTACTIC RADIOTHERAPY OR IMMUNOTHERAPY OR BOTH: A COMPARISON OF RECIST 1.1, RANO AND iRANO CRITERIA (2019) (0)
- 42. IDENTIFICATION OF BRAIN METASTASIS VULNERABILITIES USING METPLATFORM (2020) (0)
- CLIN-NEURO/MEDICAL ONCOLOGY (2012) (0)
- Buchbesprechungen·BookReviews (2009) (0)
- CSIG-22. Cd95l/Cd95 GENE DELETION DECREASES MOUSE GLIOMA TUMORIGENESIS THROUGH THE INHIBITION OF NON-CANONICAL CD95L/CD95-MEDIATED CELL GROWTH AND IMMUNOSUPPRESSION (2021) (0)
- Temozolomide, irradiation and hypoxia promote homing of hematopoietic progenitor cells towards gliomas. (2006) (0)
- European Association of NeuroOncology Editorial (2015) (0)
- Optimizing the use of alkylators in neuro-oncology (2011) (0)
- Molecular analysis of meningioma increases prognostic power: A methylation-based classification and grading system (2018) (0)
- OS2.4 Expression and relevance of tumoral and stromal MHC class II in gliomas (2016) (0)
- P08.56 Autocrine activation of the IFN signaling pathway modulates the immunogenicity of glioma cells (2017) (0)
- Antipsychotic Therapy following Neuroleptic Malignant Syndrome: A Case for Clozapine (1992) (0)
- Validation and revision of the RANO Leptomeningeal Metastasis Group scorecard for response assessment. (2019) (0)
- Kills p53 Mutant and p53 Wild-type Glioma Cells in Synergy with Irradiation and CD95 Ligand 1 (2001) (0)
- Quantifying the benefit of chemotherapy and radiation in low-grade glioma: A systematic review and meta-analysis of numbers needed to treat. (2017) (0)
- tumor infiltrating lymphocytes in glioblastoma Running title : PD-L 1 expression in glioblastoma (2017) (0)
- P18.01COMPLEMENTARY THERAPY USE IN A COHORT OF SWISS GLIOMA PATIENTS. (2014) (0)
- P13.04 Practice patterns of diagnosis and management of leptomeningeal metastasis in Europe: results from a web-based survey (2016) (0)
- SYST-03. A PHASE I/II STUDY TO EVALUATE SAFETY AND PRELIMINARY ACTIVITY OF THE TUMOR-TARGETING ANTIBODY-CYTOKINE FUSION PROTEIN L19TNF IN PATIENTS WITH GLIOBLASTOMA AT FIRST RELAPSE (2021) (0)
- Abstract 4178: L1CAM and integrin αvβ3 mediate direct cell contact between cancer stem cells and endothelial cells: Promotion of endothelial cell migration and survival (2015) (0)
- P14.25 18F-fluordesoxyglucose positron emission tomography (FDG-PET/CT) the detection of the primary lesion and staging in brain metastasis (BM) patients with cancer of unknown primary site (CUPS) (2016) (0)
- Response to Letter to Editor. (2020) (0)
- Retinal microglial cell proliferation in proliferative vitreoretinopathy (1991) (0)
- Regulational expression of the CD28-related costimulatory molecule ICOS in Multiple Sclerosis: implications for the role of costimulation in autoimmunity (2005) (0)
- Secondary prophylaxis with romiplostim for temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma. (2018) (0)
- Constitutive IFN signaling to modulate the immunogenicity of glioma cells. (2017) (0)
- Editorial : Questions regarding the optimal use of bevacizumab in glioblastoma : a moving target by (2017) (0)
- Clinical Reasoning: A 30-year-old woman with recurrent seizures and a cerebral lesion progressing over 2 decades (2014) (0)
- Ovarian Cancer by Down-Regulating Contributes to the Immune Escape of Macrophage Migration Inhibitory Factor (2013) (0)
- This information is current as in Glioma-Initiating Cells and Furin β Positive Feedback Loop of TGF-Cutting Edge : ERK 1 Mediates the Autocrine (2017) (0)
- P01.30 In vivo effects of isoform-specific inhibition of TGF-β3 in glioblastoma (2017) (0)
- Death Ligand/Death Receptor-Mediated Apoptosis for Treatment of Brain Tumors (2001) (0)
- The imaging substudy of the randomized ARTE trial: MRI and 18FET PET associations with overall survival benefit from bevacizumab in elderly patients with newly diagnosed IDH wildtype glioblastoma. (2020) (0)
- Paranoid psychosis, epidermoid tumor, and epilepsy: "symptomatic" psychosis or coincidence? (1992) (0)
- Irradiation and non-lethal hypoxia promote attraction of hematopoietic stem cells towards glioma cells by HIF1-mediated induction of CXCL12 (2005) (0)
- DDIS-04. INTERFERON-β SENSITIZES HUMAN GLIOBLASTOMA CELLS TO THE CYCLIN-DEPENDENT KINASE INHIBITOR, TG02 (2019) (0)
- DNA methylation and survival differences associated with the type of IDH mutation in 1p/19q non-codeleted astrocytomas (2020) (0)
- Effective suppression of crescendo amaurosis fugax associated with anti-phospholipid antibodies by low dose aspirin (1991) (0)
- Adjuvant chemotherapy does not prolong survival more than radiotherapy alone in people with high-grade astrocytoma (2001) (0)
- 360O Telomerase reverse transcriptase (TERT) promoter mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: Is there a link? (2020) (0)
- Neuro-oncology during the COVID-19 pandemic (2021) (0)
- Gene therapy for myositis (2010) (0)
- [Update on primary brain tumours]. (2018) (0)
- Bevacizumab: Zankapfel der Glioblastomtherapie Bevacizumab: Bone of Contention in the Therapy of Glioblastoma (2019) (0)
- Amantadine Therapy for Neuroleptic Malignant Syndrome: A Challenge for the “Glutamate Hypothesis” of Schizophrenia? (1992) (0)
- Reply to Lorenz et al.: Osteoprotegerin in the central nervous system (2004) (0)
- Hotspots in Neuro-Oncology (2013) (0)
- Management of Glioblastoma: The Road Towards Stratified Cancer Care (2012) (0)
- Abstract 203: Inhibiting invasion and stemness in glioblastoma by thymosin beta 4 gene silencing: a new therapeutic target (2014) (0)
- Subject Index Vol. 7, 2010 (2010) (0)
- Prognostic value of dynamic F-18-FET PET in the light of the updated 2016 WHO classification for gliomas (2017) (0)
- DDRE-21. LOMUSTINE AND TARGETED-CYTOKINE THERAPY: A BENEFICIAL LIAISON FOR RECURRENT GLIOBLASTOMA (2021) (0)
- Contents Vol. 60, 2014 (2015) (0)
- Neuro-oncology: the European perspective in 2011 (The 49th annual meeting of Japanese Society of Clinical Oncology educational book) -- (JSCO University: Neuro-oncology) (2011) (0)
- Imaging the glioma tropism of hematopoietic progenitor cells by two photon laser scanning microscopy and PET (2009) (0)
- P06.05 The natural HLA ligandome of glioblastoma stem-like cells: Antigen discovery for T-cell based immunotherapy (2017) (0)
- AI-010. ACTIVATION OF THE PROTOTYPICAL SFK C-Src PROMOTES ANGIOGENESIS OF HUMAN GLIOBLASTOMA (2013) (0)
- First-line temozolomide therapy and MGMT status in elderly patients with primary CNS lymphoma (2009) (0)
- IMMU-17. TARGETING GLIOBLASTOMA WITH DNAM-1-BASED CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS (2019) (0)
- OS01.6 Glioblastoma in the era of bevacizumab: an epidemiological study in the Canton of Zurich, Switzerland. (2017) (0)
- Neurologic complications of cancer immunotherapies (2019) (0)
- Targeting glioblastoma with novel immunocytokines. (2020) (0)
- Gene expression profiling of glioblastoma cell lines using cDNA microarrays: Association with response to chemotherapeutic drugs (2004) (0)
- Galectin-1-expression and effect on proliferation and migration of glioma cells (2006) (0)
- Comprar Oxford Textbook Of Neuro-Oncology | Tracy Batchelor | 9780199651870 | OXFORD (2017) (0)
- P08.48 Therapeutic targeting of TGF- β1/2 in experimental gliomas (2017) (0)
- IT-28VACCINATION AGAINST EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT III IN GLIOBLASTOMA: THE RINDOPEPIMUT COMPASSIONATE USE EXPERIENCE (2014) (0)
- OS09.3 Synergistic activity of NKG2D-based chimeric antigen receptor (CAR)-T cells and radiotherapy against glioma (2017) (0)
- αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer (2014) (0)
- Prognostic value of O-(2-[18F]-fluoroethyl)-L-tyrosine PET in relapsing oligodendroglioma (2020) (0)
- Prognostic factors in leptomeningeal metastases. (2021) (0)
- Immunotherapy for glioblastoma: a long and winding road. (2010) (0)
- Targeting of CD317 by the immunotoxin HM1.24-ETA’ to allow immunotherapy in glioblastoma patients. (2019) (0)
- Suppression of invasion-driving RGS 4 by radiation-enhanced mTOR inhibition optimizes antiangiogenesis (2017) (0)
- Concepts of Personalized Medicine in Neuro-oncology (2019) (0)
- [Structures of neurooncological science and care]. (2010) (0)
- Association of peripheral blood CD4+ T-cell depletion under temozolomide with inferior survival of patients with IDH wildtype glioblastoma. (2020) (0)
- Inhibited expression of fibronectin in laryngeal squamous cell carcinoma cell lines (1997) (0)
- DDIS-07. TG02, AN ORAL CDK INHIBITOR, INDUCES MULTIPLE CELL DEATH PATHWAYS IN HUMAN GLIOMA CELL LINES AND GLIOMA-INITIATING CELLS. (2017) (0)
- NKG 2 D Ovarian Cancer by Down-Regulating Contributes to the Immune Escape of Macrophage Migration Inhibitory Factor Wischhusen (2008) (0)
- CSIG-27. DIFFERENTIAL ELEVATION OF TERT ACTIVITY AND SENSITIVITY TO TEMOZOLOMIDE BY TYPE OF TERT MUTATION IN MGMT PROMOTER-METHYLATED GLIOBLASTOMA (2018) (0)
- Prospective evaluation of stress in patients with newly diagnosed glioblastoma and in a close partner (TOGETHER-study). (2017) (0)
- P08.36 TGF-β pathway-mediated escape from VEGF blockade is linked with angiogenesis and immune-suppression in murine glioma models. (2017) (0)
- CSIG-26. MOLECULAR DETERMINANTS OF SENSITIVITY TO PI3K/AKT/mTOR PATHWAY INHIBITION IN GLIOBLASTOMA (2018) (0)
- Erratum: Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: A prospective single-arm monocentric phase-II study (RNOP-05) (Journal of Neuro-Oncology (2011) 104 (801-809) DOI:10.1007/s11060-011-0548-y) (2011) (0)
- 10:30-11:30am Delirium in the Neurologically Injured Moderators: T. Fong and E. Kimchi The predisposing and precipitating factors for delirium in an observational cohort of 1,487 neurological patients (2019) (0)
- IMMU-39. EVALUATION OF CD317-TARGETING CAR T CELLS AS A NOVEL IMMUNOTHERAPEUTIC STRATEGY AGAINST GLIOBLASTOMA (2021) (0)
- WHO classifi cation of central nervous system tumors 2016 : integration of histological features and molecular biomarkers for improved glioma diagnostics (2016) (0)
- Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma. (2018) (0)
- Monocyte-derived HLA-G, a strong inhibitor of autologous CD4 T-cell activation, is upregulated by interferon-β in vitro and in vivo: rationale for the therapy of multiple sclerosis? (2004) (0)
- SURG-10. The evolving role of neurosurgery for central nervous system metastases in the era of personalized medicine (2021) (0)
- AI-28RECURRENT GLIOBLASTOMAS AFTER TREATMENT WITH BEVACIZUMAB. (2014) (0)
- [Gliomas – What I Have to Know in ten Questions]. (2016) (0)
- P01.041 Secondary prophylaxis with romiplostim for temozolomide-induced thrombocytopenia in newly diagnosed glioblastoma (2018) (0)
- Predictors of clinical outcome in electroconvulsive therapy (1992) (0)
- Abstract 4886: Patients withEGFRamplification but withoutEGFRvIIIexpression have improved benefit compared to those withEGFRvIIIexpression in samples of the INTELLANCE2/EORTC1410 randomized phase II trial (2019) (0)
- OS6.4 Molecular classification of meningiomas across all histological subtypes and grades (2016) (0)
- New Glioma Molecular Classification for Precise Therapeutic Decision Based on Spatially-Resolved Proteogenomics Guided by MALDI-MSI and Clinical Data Integration (2021) (0)
- IMMU-07. TUMOR STROMA–TARGETING ANTIBODY-CYTOKINE CONJUGATES TO CONVERT THE IMMUNOLOGICALLY COLD GLIOMA MICROENVIRONMENT INTO A HOT ONE (2020) (0)
- 2127 FAS/APO-1 mediated apoptosis in retinal pigment epithelial cells, modulation by cytokines (1995) (0)
- DRES-13. EXTENDED TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA: AN ANALYSIS OF THE GERMAN GLIOMA NETWORK (2016) (0)
- Effect of silencing thymosin beta 4 gene expression on stemness and invasiveness in glioblastoma. (2013) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Michael Prof. Dr. Weller?
Michael Prof. Dr. Weller is affiliated with the following schools:
